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A high-affinity, bivalent PDZ domain inhibitor
complexes PICK1 to alleviate neuropathic pain
Nikolaj R Christensen1,2,†, Marta De Luca1,†, Michael B Lever1, Mette Richner3, Astrid B Hansen1,
Gith Noes-Holt1, Kathrine L Jensen1, Mette Rathje1, Dennis Bo Jensen4, Simon Erlendsson5,
Christian RO Bartling2, Ina Ammendrup-Johnsen1, Sofie E Pedersen1, Michèle Schönauer2,
Klaus B Nissen2, Søren R Midtgaard6 , Kaare Teilum5, Lise Arleth6, Andreas T Sørensen1,
Anders Bach2, Kristian Strømgaard2, Claire F Meehan4, Christian B Vægter3, Ulrik Gether1 &
Kenneth L Madsen1,*
Abstract
Maladaptive plasticity involving increased expression of AMPA-
type glutamate receptors is involved in several pathologies, includ-
ing neuropathic pain, but direct inhibition of AMPARs is associated
with side effects. As an alternative, we developed a cell-perme-
able, high-affinity (~2 nM) peptide inhibitor, Tat-P4-(C5)2, of the
PDZ domain protein PICK1 to interfere with increased AMPAR
expression. The affinity is obtained partly from the Tat peptide
and partly from the bivalency of the PDZ motif, engaging PDZ
domains from two separate PICK1 dimers to form a tetrameric
complex. Bivalent Tat-P4-(C5)2 disrupts PICK1 interaction with
membrane proteins on supported cell membrane sheets and
reduce the interaction of AMPARs with PICK1 and AMPA-receptor
surface expression in vivo. Moreover, Tat-P4-(C5)2 administration
reduces spinal cord transmission and alleviates mechanical hyper-
algesia in the spared nerve injury model of neuropathic pain.
Taken together, our data reveal Tat-P4-(C5)2 as a novel promising
lead for neuropathic pain treatment and expand the therapeutic
potential of bivalent inhibitors to non-tandem protein–protein
interaction domains.
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Introduction
Excitatory communication between neurons in the central nervous
system relies almost exclusively on glutamatergic neurotransmis-
sion. Concordantly, most neurological and psychiatric diseases,
including devastating conditions such as neuropathic pain, feature
distinct glutamatergic components, yet very few drugs targeting
glutamate neurotransmission have been approved for clinical appli-
cations. Indeed, major efforts have been directed toward developing
compounds targeting the ionotropic NMDA (N-methyl-D-aspartate)
and AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid)-type glutamate receptors, but most such compounds have
failed during clinical development due to lack of efficacy or as a
result of unacceptable side effects (Tymianski, 2014).
An attractive alternative approach to manipulate glutamatergic
neurotransmission is to target the synaptic scaffold proteins that
orchestrate synaptic signaling complexes and dynamically regulate
the surface expression and ion conductance of the ionotropic gluta-
mate receptors in the postsynaptic density. Several of these proteins
contain PDZ (PSD-95/Discs-large/ZO-1 homology) domains that are
characterized by an elongated binding crevice, which binds the
extreme C-terminus of interaction partners, including in several
cases the ionotropic glutamate receptors themselves (Khan & Lafon,
2014). Despite the well-defined binding crevice, it has proven chal-
lenging to develop sufficiently potent small-molecule inhibitors of
PDZ domain-mediated interactions as for protein–protein interac-
tions (PPIs) in general (Laraia et al, 2015). Also, given the relatively
low micromolar affinity of the interacting C-terminal peptides, it has
likewise been difficult to develop efficacious peptide-based ligands.
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An exception is a membrane-permeable peptide ligand targeting the
postsynaptic scaffold protein PSD95 (Aarts et al, 2002), which
recently passed phase 3 clinical trial for the treatment of ischemia
after stroke (Hill et al, 2020). By generating a bivalent peptide
ligand that simultaneously target two adjacent, “tandem” PDZ
domains in PSD-95, it has been possible to dramatically enhance
efficacy affinity/avidity (low nanomolar) and plasma stability
(hours) (Sainlos et al, 2011; Bach et al, 2012).
PICK1 (protein interacting with C kinase) is another PDZ domain
containing scaffold protein found in glutamatergic neurons (Hanley,
2008). PICK1 plays a central role in synaptic plasticity (Volk et al,
2010) and is a functional dimer with two PDZ domains flanking the
central membrane binding BAR (Bin/amphiphysin/Rvs) domain,
which also mediates the dimerization (Karlsen et al, 2015). The
PICK1 PDZ domain interacts directly with the C-terminus of a
number of different membrane proteins and kinases (Staudinger
et al, 1997), including the GluA2 subunit of the AMPA receptors
(AMPARs) (Dev et al, 1999; Xia et al, 1999). Functionally, PICK1
has been shown to regulate protein kinase C (PKC)-dependent phos-
phorylation of serine 880 (S880) of the AMPAR GluA2 subunit (Lu &
Ziff, 2005), important for AMPAR trafficking during synaptic plastic-
ity (Kim et al, 2001; Chung et al, 2003; Seidenman et al, 2003;
Steinberg et al, 2006). Recent studies have further suggested a more
direct role of PICK1 in regulating AMPAR surface stabilization, inter-
nalization, and recycling (Gardner et al, 2005; Jin et al, 2006; Cao
et al, 2007; Rocca et al, 2008; Citri et al, 2010; Fiuza et al, 2017). In
this context, expression of calcium permeable (CP) AMPARs in the
process of homeostatic scaling (Clem et al, 2010) as well as in
maladaptive plasticity associated with cocaine addiction (Wolf &
Ferrario, 2010; Luscher & Malenka, 2011) and oxygen–glucose
depletion (Dixon et al, 2009) has been shown to involve PICK1.
Finally, based on studies in animal models using inhibitory
peptides, siRNA, and knock-out mice, PICK1 has been shown to be
implicated in central sensitization of neuropathic pain (Garry et al,
2003; Atianjoh et al, 2010; Wang et al, 2011, 2016). This suggests
PICK1 as a potential novel target for pharmaceutical intervention in
chronic pain conditions where blockade of its PDZ domain can
restrain unwanted sensitization by impairing glutamatergic AMPAR
signaling (Garry et al, 2003; Atianjoh et al, 2010; Wang et al, 2011,
2016). Nonetheless, development of an efficacious inhibitor of the
PICK1 PDZ has so far failed with the best inhibitors having affinities
in the sub-micromolar to micromolar range (Garry et al, 2003; Bach
et al, 2010; Thorsen et al, 2010; Marcotte et al, 2018).
Here, we present the development of a highly potent (1.7 nM)
and efficacious peptide inhibitor of PICK1 for putative neuropathic
pain treatment. Although the PICK1 PDZ domains in the functional
PICK1 dimer are presumably > 150 A˚ apart (Erlendsson et al, 2015;
Karlsen et al, 2015), we demonstrate that a bivalent peptide ligand
displays a striking ~1,000-fold increase in affinity over analogous
monomeric peptides. Size-exclusion chromatography and small
angle X-ray scattering (SAXS) demonstrate that the bivalent peptide
obtains avidity in a highly unique manner from the assembly of a
novel complex of PICK1 dimers-of-dimers. We further show that the
Tat-conjugated bivalent peptide is membrane permeable, engages
with the target protein, and interferes with the PICK1-dependent
phosphorylation of the GluA2 subunit of the AMPARs. Furthermore,
the bivalent, but not the corresponding monovalent, high-affinity
peptide can actively disrupt already established PICK1-receptor
complexes on supported cell membrane sheets, as well as interfere
with PICK1-GluA2 co-immunoprecipitation and facilitate constitu-
tive internalization of GluA2. Finally, we show that administration
of the bivalent high-affinity peptide reduces spinal cord transmis-
sion and alleviates mechanical allodynia for up to 4 h in both the
acute and chronic phase of the mouse spared nerve injury (SNI)
model of neuropathic pain. Taken together, our results demonstrate
that bivalent ligands represent a strong means to achieve high, phar-
macologically relevant affinity even when targeting protein–protein
interaction domains that only are adjacent to one another in tran-
sient oligomeric configurations of the target protein.
Results
Design and development of a high-affinity bivalent inhibitor
of PICK1
Starting from the best-known binder of the PICK1 PDZ domain,
DAT C13 (corresponding to the C-terminal 13 residues of the dopa-
mine transporter (DAT)) (Ki = 1 lM) (Madsen et al, 2005), we
sought to identify the shortest peptide sequence with conserved
affinity toward the PICK1 PDZ domain. To this end, we took advan-
tage of a fluorescence polarization (FP) competition assay using a
fluorescent tracer peptide corresponding to the C-terminal 11 resi-
dues of the DAT (OrG-C11) (Fig EV1A). The DAT C13 (C13)
competitor peptide was successively truncated from the N-terminus
and retained affinity, down to DAT-C5 (C5), while further truncation
(C4 and C3) slightly reduced affinity (Figs 1A and B, and EV1B). We
evaluated the specificity of C5 (Fig EV1C) for a broad selection of
PDZ domains (both class I and II) that were previously purified and
had known ligands (Stiffler et al, 2007). C5 (10 lM) (black column)
competed for binding to PICK1 as seen by the reduction in normal-
ized mP (milli-polarization) compared to no peptide (full line). The
C5 peptide primarily bound to the PDZ domain of PICK1, however
with notable exceptions for Scribble (Scrb1) PDZ 2/4, Na(+)/H(+)
exchange regulatory cofactor NHE-RF1 (NHERF) PDZ 2/2, and E3
ubiquitin-protein ligase PDZRN3 (Semcap3) PDZ 1/2, which were
inhibited to similar level as for PICK1 (indicated by dashed line)
(Fig EV1C). C5, however, did not compete with binding of either
domain in full binding curves, suggesting they were false positive
(Appendix Fig S1).
N-terminal modification of the C3-C5 peptides, similar to Bach
et al (2011), did not significantly affect affinity (Appendix Table S1).
To render the peptide cell permeable, we combined C5 with the
11-amino-acid cell penetration peptide from human immunodefi-
ciency virus 1 (HIV-1) and trans-activator of transcription protein
(Tat) (Richard et al, 2003; Lee et al, 2014) (YGRKKRRQRRR-
HWLKV, termed Tat-C5). To be able to do binding studies, we also
produced a fluorescent variant (5FAM-Tat-C5, Fig EV1E). Surpris-
ingly, the addition of the Tat peptide gave rise to a dramatic increase
in affinity of Tat-C5 for PICK1 (Ki = 18.3 nM), as assessed in compe-
tition with 5FAM-Tat-C5 (20 nM) (Fig 1C).
To explore the structural basis for the increased affinity, we took
advantage of the PICK1 PDZ-DAT C10 construct (Erlendsson et al,
2014). Upon displacement of the DAT C10 (triggered by protease
cleavage of the linker connecting the PDZ domain to the DAT C10
sequence) with equimolar amounts of the Tat-C5 peptide, we found
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that residues in the actual binding groove I33, I35, and I37 in bB
and L83, A87, and I90 in aB were mostly unaffected and that canon-
ical PDZ binding is therefore not compromised by conjugation of
the Tat sequence. Instead, we observed strong chemical shift
changes for several residues (G40, C44, C46, L47, Y48, and I49) in
the Cys-loop, connecting bB and bC, as well as, a negatively charged
A
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patch constituted by residues D68 and E69, opposite the canonical
PDZ domain binding groove (Fig 1D and E). Docking the Tat-C5
(blue) using the observed chemical shifts as restraints (van Zundert
et al, 2016) confirmed that canonical binding of the C5 residues
allows for the electropositive Tat residues to wrap around the PDZ
domain and simultaneously interact with D68 and E69 (Fig 1F). The
specificity of Tat-C5 for the PICK1 PDZ domain increases when
compared to the C5 peptide alone (Figs 1G and EV1C), which
suggests that the exact spatial positioning of negatively charged resi-
dues and interaction with and/or flexibility of the Cys-loop are
important for both affinity and specificity.
Based on our previous work (Bach et al, 2012), we next hypothe-
sized that the native dimeric structure of PICK1 could be targeted
using a bivalent ligand with two binding peptides connected via a
polyethylene glycol (PEG) linker. We therefore designed a range of
bivalent peptides of DATC5, which were fused at the N-terminus with
PEG linkers of different lengths, PEGn-(C5)2 (Figs 1H and EV1D). All
bivalent peptides showed > 10-fold increased affinity with an optimal
linker length determined to be 4 PEG units, P4-(C5)2, spanning ~43 A˚
(Ki = 98 nM) and giving rise to a 15-fold affinity increase compared to
monovalent C5 (Ki = 1.42 lM) (Figs 1G and EV1C). This was some-
what surprising given the average distance between the PDZ domains
of the PICK1 dimer is estimated to be ~180 A˚ (Karlsen et al, 2015).
The dimeric ligand with the longest linker (P28-(C5)2), which spans
~130 A˚, on the other hand, showed the lowest affinity (Ki = 593 nM),
presumably due to increased entropic penalty (Figs 1H and EV1D). To
render the bivalent peptide cell membrane permeable, we modified
the PEG4 linker to enable conjugation to Tat (Bach et al, 2012), which
again increased the affinity considerably (6.2 nM), as assessed in
competition with 5FAM-Tat-C5 (20 nM) (Fig 1I). The resulting
peptide Tat-PEG4-(DATC5)2, termed Tat-P4-(C5)2, was labeled with
tetramethylrhodamine (TMR) (TMR-Tat-P4-(C5)2), and saturation
binding curves also demonstrated low nanomolar affinity
(Appendix Fig S2). Finally, no binding of Tat-P4-(C5)2 was observed
to another bivalent target, PSD95, whereas an analogous dimeric inhi-
bitor with a PSD95 specific sequence showed potent binding (Bach
et al, 2009) (Fig EV1F).
Finally, using low concentration (2 nM) of 5FAM-Tat-C5 as
optimal tracer (highest affinity) (Huang, 2003), we obtained final
affinities for Tat-C5 (Ki = 13.3 nM/125-fold increase over C5) and
Tat-P4-(C5)2 (Ki = 1.7 nM/994-fold increase over C5) (Figs 1J and
EV1G), respectively, ranking Tat-P4-(C5)2 among the most potent
PDZ domain inhibitors. This affinity gain was ~15-fold from the
bivalency and additional ~50-fold from the Tat sequence. Impor-
tantly, the peptides also potently competed with DAT and GluA2
tracers although this was challenging to assess due to inhibitor
depletion in the assay (Appendix Fig S3).
Previous studies on the analogous PSD95 peptides have demon-
strated that Tat conjugation as well as the PEG linker does not
merely increase binding strength but also increases plasma stability,
which is crucial for in vivo administration. Similarly, we observed
that whereas the C5 peptide was completely degraded, ~5% of Tat-
C5 and more than 50% of Tat-P4-(C5)2 endured incubation with
human plasma for 24 h (Fig EV1H), making these peptides relevant
for in vivo application.
Tat-P4-(C5)2 dissociates PICK1 from
membrane-embedded receptors
PICK1 serves its functional role as a scaffold protein interacting via
its PDZ domain with receptors, transporters, and ion channels
embedded in the cell membrane. To determine the efficacy of Tat-
P4-(C5)2 and Tat-C5 to interfere with PICK1 binding to membrane-
embedded proteins, we took advantage of the supported cell
membrane sheet (SCMS) approach (Erlendsson et al, 2019)
(Fig 2A). Using this approach, we recently demonstrated that PICK1
interacts with membrane-embedded Tac-YFP-DAT C24 (the single
transmembrane IL2 subunit fused to YFP and the 24 C-terminal resi-
dues of DAT) with a binding strength of ~50 nM (Erlendsson et al,
2019). First, we pre-incubated fluorescently labeled recombinant rat
PICK1 (300 nM SNAP543-PICK1) with increasing concentrations of
C5, Tat-C5, or Tat-P4-(C5)2 to compete for binding to SCMSs
expressing Tac-YFP-DAT C24 (Fig 2B–D and Appendix Fig S4). The
IC50 values (C5 = 3.80 lM; Tat-C5 = 101 nM; Tat-P4-(C5)2 = 7.0 nM)
were slightly weaker than the affinities obtained by FP competition
binding, but confirmed the dimeric ligand as a superior inhibitor of
PICK1. Next, we determined the ability of the peptides to dissociate
pre-bound PICK1 from the SCMS. Following pre-incubation of
◀ Figure 1. Development of a high-affinity bivalent inhibitor of PICK1s.A Primary sequence of 5-mer peptide (C5) derived from the dopamine transporter C-terminus and the Tat-conjugated variant, Tat-C5.
B Fluorescence polarization (FP) competition derived affinity assessment of consecutive truncations of the DAT C13 C-terminus as indicated by the sequences. Bars
indicate the mean fold change relative to C13 (Ki = 1.69 lM). Data are shown as mean with error bars as SEM with n = 6. Representative binding curves are shown
in Fig EV1A.
C FP competition binding of C5 and Tat-C5 to PICK1 with 5FAM-Tat-C5 (20 nM) as tracer. Saturation binding curve is shown in Fig EV1B.
D Backbone amide chemical shift changes (DdHN) of PICK1-PDZ-C10 after addition of Tat-C5 and addition of protease to cleave C10 from the PDZ domain and allow
exchange. Numbers refer to residue number in PICK1 (UniProt: Q9EP80). Red bars indicate a chemical shift larger than mean+SD.
E 1H-15N-HSQC 2D spectra of PICK1-PDZ-C10 (orange) following addition of Tat-C5 (green) and subsequent addition of protease (red) to allow for exchange between
C10 and Tat-C5.
F Docking model, for visual purposes, of PICK1-PDZ (PDB: 2LUI) in complex with Tat-C5 (blue), with perturbed residues indicated from (D) in red.
G Selectivity screen for Tat-C5 against a selection of 42 purified PDZ domains performed with a fixed concentration of Tat-C5 (10 lM) in competition with PDZ
domains and their respective fluorescent ligands. Data are normalized to binding in absence of peptide (full line). Dashed line represents the level of competition
obtained for PICK1. Screen for C5 can be seen in Fig EV1C.
H Affinity gain of bivalent C5 peptides (Pn-(C5)2) N-terminally conjugated with different length PEG linkers as indicated. Bars indicate the mean fold change relative to
C5 (Ki = 1.69 lM). Data are shown as mean with error bars as SEM with n = 6. Representative binding curves are shown in Fig EV1C.
I FP competition binding of C5 (also used in C) and Tat-P4-(C5)2 to PICK1 with 5FAM-Tat-C5 (20 nM) as tracer.
J Structure and highest obtained affinity of C5, Tat11-C5, and Tat11-P4-(C5)2 toward PICK1.
Data information: Data points and bars are shown as mean with error bars as SEM of n ≥ 3. Docking in (F) was done using HADDOCK (van Zundert et al, 2016), with
residues indicated from (D) as essential residues for interaction, but no further restraints, therefore being only for visual purposes.
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fluorescently labeled PICK1 on SCMSs expressing Tac-YFP-DAT
C24, unbound PICK1 was washed away before incubation with
increasing concentrations of C5, Tat-C5, or Tat-P4-(C5)2 (Fig 2E–G
and images supporting the full curves and method in Fig EV2A–E).
Strikingly, Tat-P4-(C5)2 increased the macroscopic off-rate of biva-
lently bound PICK1 with an apparent IC50 = 1.17 lM, whereas
neither C5 nor Tat-C5 significantly dissociated PICK1 from SCMSs.
PICK1 pre-binding to the sheet is likely to give rise to depletion of
the inhibitors, which means that we can probably not translate the
absolute potency obtained from the experiment to a neuronal
setting. The relative difference, however, is striking and suggests a
unique advantage of the dimeric ligand in a therapeutic context
where the ability to dissociate a preformed complex predictably
would be highly advantageous.
High affinity of Tat-P4-(C5)2 results from complex assembly with
tetrameric PICK1
We recently demonstrated that PICK1 forms elongated oligomers in
solution using SAXS. Interestingly, the PDZ domains between the
individual dimers were predicted to be in much closer proximity than
the two PDZ domains within the dimers (Karlsen et al, 2015). We
therefore wanted to assess whether the dimeric Tat-P4-(C5)2 peptide
potentially could stabilize higher order PICK1 complexes. In analyti-
cal size-exclusion chromatography (SEC), purified PICK1 eluted with
a main peak at ~12 ml (Fig 3A, pink), which, according to our previ-
ous studies, corresponds to dimeric PICK1 (Karlsen et al, 2015;
Madasu et al, 2015). The SEC profile was unchanged by incubation
with Tat-C5 (Fig 3A). Upon incubation with Tat-P4-(C5)2, however,
the main elution peak shifted ~1 ml toward a larger hydrodynamic
radius far above the hypothetical increase of 3 or 6 kDa resulting
from binding of 1 or 2 bivalent peptides, respectively (Fig 3B, light
blue). Incubation of PICK1 with the fluorescently labeled TMR-Tat-
P4-(C5)2 peptide showed overlapping curves of the 280 nm absor-
bance and the 546 nm fluorescence, confirming that the left-shifted
peak indeed contained both PICK1 and the peptide, whereas the void
peak (8 ml) showed no peptide binding (Fig 3C). To address the stoi-
chiometry of the complex, we incubated a fixed amount of PICK1
(40 lM) with increasing concentrations of Tat-P4-(C5)2 (Fig 3D and
E) and found that, at a molar ratio of 1:4 (Tat-P4-(C5)2:PICK1), all
dimeric PICK1 (blue line) was shifted into the complexed state (green
line), indicating that complex formation involves 1 bivalent peptide
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Figure 2. High-affinity PDZ inhibitors can dissociate PICK1 from transmembrane interaction partner.
A Illustration of supported cell membrane sheet (SCMS) assay.
B Representative confocal images of SCMS expressing Tac-YFP-DATC24 incubated with pre-complexed fluorescently labeled PICK1 and unlabeled peptides as indicated
(10 nM), scale bar 10 lm. Full concentration curves shown in Appendix Fig S4 and include the representative images shown here.
C SCMS derived competitive binding curves for peptides as indicated, red line indicates 10 nM as shown in representative images.
D Experimental outline of pre-incubation with peptide.
E Representative confocal images of SCMS expressing Tac-YFP-DATC24, incubated with fluorescently labeled PICK1 and subsequently unlabeled peptide as indicated
(10 lM). Scale bar 10 lm. Full concentration curves shown in Fig EV2 and include the representative images shown here.
F Efficacy of the peptides as indicated to facilitate dissociation of PICK1 from SCMS, red line indicates 10 lM as shown in representative images.
G Experimental outline post-incubation with peptide.
Data information: Data points are shown as mean with error bars as SEM of n ≥ 14. Curves were fitted to a log dose response (three parameters) extracting the IC50
using GraphPad Prism 7.0. Data points in (F) were compared at different concentrations using two-way ANOVA followed by Tukey’s multiple comparison test
(****P < 0.0001).
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and two PICK1 dimers. At peptide to protein ratios above 1:4, the
complex started to precipitate and could be pelleted by centrifugation
(Fig 3F). To assess whether the ability of Tat-P4-(C5)2 to form higher
order PICK1 complexes was dependent on the dimeric assembly of
the BAR domain, PICK1 was dissociated into a monomeric state
using detergent (0.1% Triton X-100) (Karlsen et al, 2015). Mono-
meric PICK1 eluted at 12.7 ml, and interestingly, a 1 ml shift was
still observed upon incubation with Tat-P4-(C5)2. Moreover,
Tat-P4-(C5)2 still maintained an affinity gain in FP binding of > 300-
fold compared to C5, demonstrating that complex formation is inde-
pendent of the dimeric BAR domain (Appendix Fig S5 and
Appendix Table S2).
To elucidate the number of PICK1 subunits in the complex
stabilized by Tat-P4-(C5)2 and to further investigate its structure,
we used SAXS. Data were collected for a concentration range of
0.5–2.5 mg/ml for PICK1 both in absence and presence of
Tat-P4-(C5)2 (Fig 3G–J and Appendix Table S3). The SAXS data
and the corresponding pair distance distribution functions, p(r),
obtained by Bayesian Indirect Fourier transformations (www.baye
sapp.org) for PICK1 alone (Fig 3H) changed considerably by incu-
bation with Tat-P4-(C5)2 (Fig 3J), suggesting major conformational
changes to the quaternary structure. The changes were most
evident at low q/long distances (Fig 3K), indicating that the
concentration-dependent large oligomer formation previously
observed for PICK1 (Karlsen et al, 2015) was absent from the
complex with PICK1:Tat-P4-(C5)2. Moreover, whereas the forward
scattering, I(0), of PICK1 without Tat-P4-(C5)2 showed a clear
concentration dependence consistent with oligomerization as
previously observed (Karlsen et al, 2015), I(0), of the PICK1:Tat-
P4-(C5)2 complex averaged ~4 PICK1 masses (229 kDa) across the
PICK1 concentration range without any concentration dependence
(Fig 3G–K, and Appendix Table S3). In conclusion, this demon-
strates the formation of a stable, compact, tetrameric PICK1
complex by Tat-P4-(C5)2. Although structurally stabilized by
Tat-P4-(C5)2, PICK1 was still flexible in solution (Appendix Fig
S6) and its shape cannot be represented by a single rigid structure
(Karlsen et al, 2015). Consequently, we used ensemble optimiza-
tion method (EOM) (Bernado´ et al, 2007; Tria et al, 2015) on the
2 mg/ml dataset of PICK1 with Tat-P4-(C5)2 to investigate the
structural organization of the complex. EOM sampling of multiple
configurations of dimeric PICK1 fitted the data poorly (Fig EV3A–
C), so we constructed tetrameric configurations of PICK1, includ-
ing a circular (Fig EV3D–F), elongated (Fig EV3G–I), and a side-
by-side configuration (Fig EV3J-L) and tested how they fitted the
data. The most reliable fit of the SAXS data (simple model, low
v2) was obtained for a configuration of a compact tetrameric state
(Fig EV3J–L), where the BAR domains align in a side-by-side con-
figuration (Fig 3J) and the molecular model corresponding to this
configuration is shown in Fig 3L. Taken together, the model inde-
pendent SAXS analysis show that Tat-P4-(C5)2 induces a stable,
compact, tetrameric state of PICK1 with the EOM analysis
suggesting configurations with the PDZ domains from two individ-
ual PICK1 dimers within distances that can be bridged by the
bivalent peptide.
Tat-C5 and Tat-P4-(C5)2 are membrane permeable and interfere
with hippocampal PICK1 function ex vivo
To confirm that the Tat sequence confers membrane permeability,
dissociated hippocampal neurons were incubated with the TMR-
labeled peptides TMR-Tat-P4-(C5)2, TMR-Tat-C5, or TMR-C5
together with the membrane dye DiO. Both of the Tat-fused peptides
labeled neurons, whereas C5 alone did not (Fig 4A). Inspection of
the 3D profile of the somatic region further revealed that the DiO
staining, and thus membrane, surrounded a substantial fraction of
the fluorescent signal from both TMR-Tat-P4-(C5)2 and TMR-Tat-C5,
consistent with presence of the peptides in the cytosol (Fig 4A,
boxed area highlighted in right panels). TMR-Tat-C5 in general,
however, showed a more punctate distribution, whereas the TMR-
Tat-P4-(C5)2 was mostly diffuse (Fig 4A).
◀ Figure 3. Tat-P4(C5)2, but not Tat-C5, reconfigures PICK1 into a novel tetrameric state.A Size-exclusion chromatography (SEC) profiles of PICK1 in absence (pink, Absmax = 11.7 ml) and presence of Tat-C5 (purple, Absmax = 11.7 ml).
B SEC profiles of PICK1 in absence (pink, Absmax = 11.7 ml) and presence of Tat-P4-(C5)2 (blue, Absmax = 10.7 ml).
C SEC profiles of PICK1 in absence (pink, Absmax = 11.7 ml) and presence of TMR-Tat-P4-(C5)2 (blue (abs280 nm), red (abs544 nm), Absmax = 10.7 ml).
D Representative SEC profiles of PICK1 (40 lM) incubated with increasing concentration of Tat-P4-(C5)2, colors indicate Gaussian fits of respective population, (red)
aggregates/Void, (blue) dimeric PICK1, (green) oligomeric PICK1, (orange) unbound Tat-P4-(C5)2.
E Quantification of abs280 at Evol = 11.7 ml (dimer—blue) and Evol = 10.7 ml (tetramer—green) as a function of concentration (0-10 lM) of Tat-P4-(C5)2. Light blue line
indicates tetramer fraction of total PICK1.
F SDS–PAGE sedimentation assay showing increased amounts of PICK1 in the pellet (P) fraction with increasing concentrations of Tat-P4-(C5)2. PICK1~50 kDa,
Tat-P4-(C5)2~10 kDa. S denotes supernatant fraction.
G Small angle X-ray scattering (SAXS)-derived scattering curves of a concentration range of PICK1 on absolute scale show concentration-dependent aggregation.
H Pair distance distribution function (pddf) of PICK1 in absence of Tat-P4-(C5)2, indicating very large protein complexes present in sample.
I SAXS-derived scattering curves of a concentration range of PICK1 in complex with Tat-P4-(C5)2 on absolute scale show minor concentration-dependent aggregation.
J Pair distance distribution function (pddf) of a concentration range of PICK1 in presence of Tat-P4-(C5)2, indicating a smaller complex than for PICK1 in absence of
Tat-P4-(C5)2.
K Scattering difference (DI(q) = I(q)PICK1+Tat-P4-(C5)2 – I(q)PICK1) between PICK1 in presence and absence of Tat-P4-(C5)2 at indicated concentration shows a clear
difference in scattering below 0.1 Å1.
L Proposed EOM ensemble for PICK1, in complex with Tat-P4-(C5)2 (not visible in structure) with shading according to model ensemble percentage (10/20/70%).
C-terminal unstructured regions are removed for clarity.
Data information: In (A), all elution profiles were normalized to the lowest and highest main elution peak. In (D), elution profiles were normalized to the lowest and
highest points of PICK1 in absence of Tat-P4-(C5)2. In (G and H), the pddf was fitted using BayesApp. EOM fits were done using known structures of PICK1 PDZ domain
(PDB: 2LUI) and the previously published model for the dimeric BAR domain, connected by full flexible linkers, N- and C-terminal. Model in (L) was prepared
using PyMoL.
Source data are available online for this figure.
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To enable visualization of synaptic PICK1, we used a knock-
down and replacement strategy (Citri et al, 2010) to exchange
endogenous PICK1 with GFP-PICK1 in hippocampal neurons
(Fig 4B). As previously shown, GFP-PICK1 colocalized with GluA2
containing AMPARs, both in the somatic region and in punctate
structures associated with the dendritic compartment (Fig 4B, zooms).
Upon incubation (1 h) of the neurons with TMR-Tat-P4-(C5)2, we
observed a punctate localization of the peptide signal that was asso-
ciated with dendritic structures outside the somatic region and this
signal showed partial overlap with the GFP-PICK1 and GluA2 signal
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(Fig 4B, zooms). These data demonstrate penetration of Tat-P4-(C5)2
into neurons and are consistent with subsequent in vitro target
engagement of Tat-P4-(C5)2 with PICK1.
To further substantiate this conclusion, we knocked down PICK1
expression (without replacement) in the hippocampal neurons,
which significantly reduced the amount of TMR-Tat-P4-(C5)2 signal
in agreement with the reduced level of the target (Appendix Fig S7).
We also observed clear colocalization of the TMR-Tat-P4-(C5)2
signal with GFP-PICK1 in HEK293 cells; however, this colocalization
was neither seen for a PICK1 mutant with compromised PDZ bind-
ing (GFP-PICK1 A87L) nor with GFP alone (Appendix Fig S8A–I).
The compromised binding of PICK1 A87L to TMR-Tat-P4-(C5)2 was
confirmed by FP binding (Appendix Fig S8K). Finally, we were able
to pull down GFP-PICK1, but not GFP-PICK1 A87L, from the trans-
fected HEK293 cells using a biotinylated Tat-P4-(C5)2 (Appendix Fig
S8J), directly supporting target engagement of TMR-Tat-P4-(C5)2
with PICK1.
To address if Tat-P4-(C5)2 or Tat-C5 could disrupt the interaction
between PICK1 and AMPARs in neurons, we performed co-immuno-
precipitation (co-IP) experiments. Incubation of hippocampal slices
with Tat-P4-(C5)2, or Tat-C5, significantly reduced the co-IP of
GluA2 by PICK1 (Fig 4C and D). Similarly, a reduction was
observed in the reverse co-IP (Appendix Fig S9). Next, we addressed
whether the peptides could interfere with the functional regulation
of AMPARs by PICK1. Indeed, both peptides significantly reduced
phosphorylation of Ser880 in GluA2 (Lu & Ziff, 2005), both under
basal conditions and after a chemical long-term depression (LTD)
protocol involving NMDAR-dependent kinase activation (Fig 4E–H).
Finally, since PICK1 is believed to play a critical role in AMPAR
trafficking, we addressed whether the peptides might affect GluA2
internalization in cultured hippocampal neurons. Somewhat surpris-
ingly, Tat-P4-(C5)2 significantly increased constitutive internaliza-
tion of surface labeled GluA2. Activation of protein kinase C (PKC)
by PMA treatment further increased GluA2 internalization, which
occluded the effect of Tat-P4-(C5)2 (Fig 4I and J). Importantly, we
observed a similar effect on GluA2 trafficking upon shRNA-
mediated knock-down of PICK1 (Appendix Fig S10A–C). In
contrary, Tat-C5 neither affected constitutive nor PMA induced
GluA2 internalization (Appendix Fig S10D–F). In summary, these
data support that both peptides are membrane permeable and
reduce GluA2 S880 phosphorylation, but only Tat-P4-(C5)2 can
disrupt the PICK1:GluA2 complex and increase constitutive internal-
ization of GluA2.
Tat-P4-(C5)2, but not Tat-C5, reduces functional interaction of
PICK1 with AMPAR in the spinal cord
PICK1 has been proposed as a putative target for treatment of
neuropathic pain (Garry et al, 2003; Wang et al, 2011, 2016). To
address pharmacokinetic and pharmacodynamic properties
in vivo, peptides were administered intrathecally (i.t.) in naı¨ve
mice. TMR-Tat-P4-(C5)2 and TMR-Tat-C5 (20 lM) were clearly
visible in both the ventral and dorsal parts of the spinal cord 1 h
after injection (Fig 5A). Moreover, TMR-Tat-C5 (Fig 5A, bottom)
appeared to distribute more homogenously to the gray matter part
of the spinal cord than TMR-Tat-P4-(C5)2 (Fig 5A, top). Adminis-
tration of Tat-P4-(C5)2 also reduced co-IP of GluA2 by PICK1 from
the spinal cord (Fig 5B), similar to our observation in hippocam-
pal slices, whereas Tat-C5 did not significantly reduce GluA2 co-
IP by PICK1 (Fig 5C), suggesting different pharmacodynamic/
kinetic properties of the two peptides also in the spinal cord upon
i.t. administration. Next, we tested the effect of both peptides on
GluA2 Ser880 phosphorylation levels on spinal cord slices and, in
contrast to hippocampal slices, Tat-P4-(C5)2, but not Tat-C5,
significantly reduced GluA2 S880 phosphorylation (Fig 5D). To
address putative effects on AMPAR surface levels, we performed
surface biotinylation experiments on spinal cord slices. Neither
peptides affected GluA1 surface levels, whereas both peptides
gave rise to a small but non-significant reduction in surface
GluA2 levels (Fig 5E). Lastly, the ability of Tat-P4-(C5)2 to engage
the target protein in vivo following i.t. administration in naı¨ve
mice was confirmed by a pull-down experiment between
PICK1 protein and an N-terminally biotinylated Tat-P4-(C5)2
peptide (Fig 5F).
◀ Figure 4. Tat-P4-(C5)2 is membrane permeable and compromise PICK1:GluA2 functional interaction in hippocampal neurons.A Representative confocal images of hippocampal neurons showing membrane penetration of TMR-Tat-P4-(C5)2 and TMR-Tat-C5 (5 lM) (magenta), but not the control
TMR-C5 (all 20 lM). The cell membrane was stained with DiO (gray). Scale bars: 10 lm and 5 lm on the zooms/orthogonal views.
B Representative confocal images of hippocampal neurons transduced with the viral vector encoding GFP-PICK1 and incubated with 5 nM TMR-Tat-P4-(C5)2. Partial
colocalization between TMR-Tat-P4-(C5)2 (red), GFP-PICK1 (green), and GluA2 (blue) is seen in insert zooms. Experiment was done three times. Scale bars: 10 lm and
1 lm on the zooms.
C Representative immunoblots from hippocampal slices following treatment with Tat-P4-(C5)2 or Tat-C5 (bath application, 20 lM).
D Densitometric analysis of immunoblots from (C) shows reduced PICK1:GluA2 Co-IP following incubation with Tat-P4-(C5)2 but not Tat-C5. Bar graphs show mean with
error bars as SEM (one-way ANOVA followed by Dunnett’s multiple comparison test, ***P ≤ 0.001, n = 4/group).
E Representative immunoblots from hippocampal slices following Tat-P4-(C5)2 bath application (20 lM) show reduction in the phosphorylation level of S880 GluA2
both under basal condition and after chemical LTD (cLTD).
F Bar graphs show densitometric analysis of immunoblots from (E).
G Representative immunoblots from hippocampal slices following Tat-C5 bath application (20 lM) show reduction in the phosphorylation level of S880 GluA2 both
under basal condition and after chemical LTD (cLTD).
H Bar graphs (right panel) show densitometric analysis of immunoblots from (G).
I Representative confocal images of hippocampal neurons stained for surface GluA2 (sGluA2, light blue) and internalized GluA2 (iGluA2, red). Treatment with
Tat-P4-(C5)2 (20 lM) significantly increases the constitutive, but not PMA induced internalization. Scale bars 10 lm.
J Quantification of iGluA2/sGluA2 within the region of interest for individual neuron (see I, top right corner). Tat-C5 did not increase GluA2 internalization (see
Appendix Fig S9D–F).
Data information: Statistics in (F and H) was done by two-way ANOVA, followed by Sidak post-test, which revealed a significant effect of the peptide (F(1, 192) = 27,17),
*P ≤ 0.05, **P ≤ 0.01, n = 4–8 as indicated by individual values. Similar analysis in (J), PMA treatment (F(1, 192) = 217.6)) and a significant interaction factor (F(1,
192) = 40,39), ****P ≤ 0.0001, n = 46–50 neurons/group as indicated by individual values. All data expressed as mean with error bars as SEM.
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Figure 5. Tat-P4-(C5)2 interferes with PICK1:GluA2 functional interaction in mouse spinal cord.
A Representative coronal slices from lumbar spinal cord show the presence of both TMR-Tat-P4-(C5)2 and TMR-Tat-C5 peptides (magenta) 1 h after i.t. administration in
naïve mice. Scale bar 200 lm. DH dorsal horn, VH ventral horn. Insert zooms of merged channels (right panels), scale bar 50 lm.
B Representative immunoblots of co-immunoprecipitated PICK1:GluA2 from spinal cord lumbar tract total lysates demonstrate partial disruption of this interaction 1 h
after 20 lM i.t. injection of Tat-P4-(C5)2. Densitometric analysis of immunoblots indicates a significant effect following Tat-P4-(C5)2 treatment, and graph shows
mean  SEM and individual points, unpaired t-test, **P ≤ 0.01, n = 4/group.
C Representative immunoblots of co-immunoprecipitated PICK1:GluA2 from spinal cord lumbar tract total lysates demonstrates no disruption of this interaction 1 h
after 20 lM i.t. injection Tat-C5. Densitometric analysis of immunoblots indicates no significant effect of Tat-C5, and graph shows mean  SEM and individual
points, unpaired t-test, P = 0.10, n = 4/group.
D Representative immunoblots of lumbar spinal cord total lysates exhibit decreased pS880-GluA2 total levels following 20 lM Tat-P4-(C5)2, and Tat-C5 i.t. injections
compared to saline injected animals. Densitometric analysis of immunoblot indicates a significant effect only for Tat-P4-(C5)2 (graph show mean  SEM and
individual points, one-way ANOVA followed by Dunnett0s multiple comparison test, **P ≤ 0.01, n = 5–6/group as indicated by individual values).
E Surface biotinylation of spinal cord slices under basal condition demonstrates unchanged GluA1 and GluA2 surface level upon Tat-P4-(C5)2, Tat-C5 peptides
incubation compared to the untreated condition (CTR). Densitometric analysis of immunoblots shows that the reduction in mean surface for GluA2 in not significant
(graph show mean  SEM and individual points, one-way ANOVA followed by Dunnett0s multiple comparison test, n = 5/group as indicated by individual values).
F Immunoblot of PICK1 following pull-down from lumbar spinal cord with Biotin-Tat-P4-(C5)2 or Biotin following 20 lM i.t. administration demonstrating in vivo target
engagement.
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Tat-P4-(C5)2, but not Tat-C5, reduces surface AMPAR levels to
alleviate neuropathic pain
To test whether the PICK1 inhibitors can alleviate neuropathic pain
symptoms that involve central sensitization, we employed the
spared nerve injury model (SNI) on adult mice (Decosterd & Woolf,
2000; Fig 6A). On day two after the nerve injury, the model
produced a robust hypersensitivity (reduced paw withdrawal
threshold (PWT)) to mechanical stimuli applied to the ipsilateral
hind paw without affecting the contralateral hind paw (Fig 6B). I.t.
administration of Tat-P4-(C5)2 significantly alleviated SNI-induced
hypersensitivity 1 h after administration (compared to the pre-injec-
tion time point, 0 h) reaching a level similar to both the contralat-
eral paw and pre-injury level. The pain threshold was still
significantly increased at 3 h (compared to the pre-injection time
point, 0 h), while no effect of the peptide was seen after 24 h
(Fig 6B). Intraplantar administration of the same dose did not affect
PWT and even a 10-fold higher intraplantar dose did not signifi-
cantly alleviate allodynia (Appendix Fig S11), suggesting little
peripheral effect of Tat-P4-(C5)2.
In concordance with our previous results, i.t. administration of
C5 did not affect the PWT, neither did Tat-C5 (Figs 6C and EV4A).
Also, the small-molecule inhibitor of PICK1 FSC231 (Thorsen et al,
2010) as well as a myristoylated GluA2 inhibitory peptide (Garry
et al, 2003) failed to elicit a significant effect on the PWT (Fig EV4B
and C), whereas gabapentin, a first-line treatment for neuropathic
pain, reversed PWT to baseline levels of the contralateral paw and
prior to nerve injury of the ipsilateral paw (Fig EV4D). Surface
biotinylation on spinal cord slices showed upregulation of both
surface GluA1 and GluA2 following SNI, while treatment of SNI
animals with Tat-P4-(C5)2, but not Tat-C5, reduced the surface level
of both GluA1 and GluA2 below control level (Fig 6D).
Following i.t. administration in SNI animals, TMR-Tat-P4-(C5)2
initially (0 min and 30 min) distributed along the white matter of
the spinal cord, and at later time points (60 min and 120 min), it
was clearly visible in the gray matter as well (Fig 6E). We also
noticed that the peptide signal in the gray matter was exclusively
confined toward neurons (NeuN) (Fig 6F) and not on glial cells
(GFAP) (Appendix Fig S12), suggesting neuronal tropism of TMR-
Tat-P4-(C5)2.
Mice subjected to SNI showed similar alleviation of mechanical
allodynia after the first (2 days after operation) and second (3 days
after operation) administration of Tat-P4-(C5)2 (Appendix Fig S13)
indicating no development of tolerance for Tat-P4-(C5)2 upon
repeated administration. Using this setup, we could also demon-
strate that the effect of Tat-P4-(C5)2 on PWT was dose-dependent
(Fig 6G). Administration of Tat-P4-(C5)2 also significantly increased
PWT of the animals at 14 days after injury and again at 28 days
after injury (Fig 6H). Initial inflammation ceases 9–10 days after
surgery, and therefore, these later time points are believed to better
mimic chronic pain in humans (Percie du Sert & Rice, 2014).
Injected gabapentin had comparable efficacy 14 days after nerve
injury (Appendix Fig S14), suggesting that Tat-P4-(C5)2 may be an
attractive lead for development of efficacious neuropathic pain ther-
apy.
Tat-P4-(C5)2 represses expression of CP-AMPARs and reduce
neurotransmission in the dorsal horn of SNI mice
Both inflammatory and neuropathic pain models have been shown
to cause an upregulation of CP-AMPARs (Vikman et al, 2008;
Gangadharan et al, 2011; Chen et al, 2013). Since PICK1 has been
shown to underlie maladaptive expression of CP-AMPARs in
midbrain and hippocampus (Dixon et al, 2009; Wolf & Ferrario,
2010; Luscher & Malenka, 2011), we asked whether this might also
be the case in the spinal cord. To assess functional expression of
CP-AMPARs in neurons, we used kainate-induced cobalt uptake on
spinal cord slices and as previously reported modest staining of
cobalt was observed under basal conditions (Fig 7Ai and B) (Engel-
man et al, 1999). To mimic the effect of peripheral injury on spinal
◀ Figure 6. Tat-P4-(C5)2, but not Tat-C5, reduce AMPAR surface expression and allodynia in SNI model of neuropathic pain.A Diagram of in vivo timeline (D = day).
B i.t. administration (20 lM) of Tat-P4-(C5)2 significantly reduced ipsilateral paw hypersensitivity of SNI mice in the initiation stage (2 days after injury) of the spared
nerve injury model at time points 1 and 3 h (n = 7).
C i.t. administration (20 lM) of Tat-C5 did not affect ipsilateral paw hypersensitivity of SNI mice in the initiation stage (2 days after injury) of the spared nerve injury
model (n = 8).
D Representative Western blots (top) for GluA1 and GluA2 following surface biotinylation of spinal cord slices. Densitometric analysis (bottom) of immunoblots. We
observed upregulation of both GluA1 and GluA2 surface levels following SNI surgery compared to non-operated animal CTL (unpaired t-test GluA1: t(4) = 3.372,
GluA2: t(4) = 3.991,#P ≤ 0.05, n = 3/group). Tat-P4-(C5)2 but not Tat-C5 significantly reduced the SNI-induced GluA2 surface expression and shows a strong tendency
for GluA1 as well. Representative immunoblot shows unaltered PICK1 total level in the total lysate in the four conditions.
E Images of lumbar spinal cord sagittal sections showing the time course of TMR-Tat-P4-(C5)2 (magenta) after i.t. administration (20 lM) in SNI mice showing maximal
accumulation in cells after 60 min. Scale bar 1,000 lm and 100 lm in zooms.
F Overlay with immunohistochemical staining for the neuronal marker NeuN (yellow) highlights strong neuronal tropism of TMR-Tat-P4-(C5)2 (magenta). Scale bar 100
lm.
G Dose-dependent von Frey test in the acute phase (2 days after injury) of the spared nerve injury model following i.t. administration of Tat-P4-(C5)2 (n = 8/group) did
not affect ipsilateral paw hypersensitivity of SNI mice and lasts up to 4 h post-injection.
H i.t. administration of Tat-P4-(C5)2 (20 lM) at days 14 and 28 after injury in the maintenance phase of SNI model in mice shows significant increase in pain
withdrawal threshold up to 3 h with equal efficacy in male and female mice (compared to time 0 pre-injection, D14 n = 8/group/gender, D28 n = 6 male, n = 7
female).
Data information: In (B and C), ipsi- and contralateral paw withdrawal thresholds at different time points were compared to time 0 using two-way repeated-measures
ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, ****P < 0.0001). In (D), GluA1/Pan-Cadherin levels were compared using one-way ANOVA followed by
Dunnett0s multiple comparison test, GluA2: F(2,6)=6.256, *P ≤ 0.05; GluA1: F(2,6)=2.843 P = 0.096, n = 3/group). In (G), ipsi- and contralateral paw withdrawal thresholds at
different time points were compared to time 0 using two-way ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01, ****P < 0.0001). All data
expressed as mean  SEM. In (H), ipsi- and contralateral paw withdrawal thresholds at different time points were compared to time 0 using two-way repeated-
measures ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01, ****/####P < 0.0001).
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cord slices, we applied TNFa which gave rise to robust induction of
CP-AMPAR function (Fig 7Aii and B) (Xu et al, 2006; Wigerblad
et al, 2017), and indeed, this induction was significantly decreased
by co-incubation of TNFa with Tat-P4-(C5)2 (20 lM) (Fig 7Aiii and
B), suggesting that Tat-P4-(C5)2 can interfere with functional expres-
sion of CP-AMPARs as one mechanism to reduce pain transmission.
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Finally, to directly determine the effect of Tat-P4-(C5)2 on DRG
excitability and transmission in the spinal cord, in vivo electrophysi-
ological recordings were performed in adult decerebrate SNI mice to
avoid possible interactions with anesthetics (Fig 7C and D). Hyper-
sensitivity of the operated animals was confirmed by von Frey
measurements prior to DRG excitability and transmission experi-
ments (threshold for injured paw in individual mice is depicted in
parenthesis Fig 7F and H). The sural nerve was stimulated and the
incoming volley of action potentials along the DRG were recorded
(Lloyd and McIntyre 1948), together with the resulting field poten-
tials in the spinal cord at depths consistent with lamina 1 and 2
(Fig C, D).
Baseline recordings were made before Tat-P4-(C5)2 (20 lM) was
applied to the exposed surface of the spinal cord and recordings
performed again in the same location approximately 30 min after
peptide application. Averaged field potentials in the spinal cord at
depths corresponding to lamina 1 and lamina 2 were significantly
reduced at 30 min following peptide administration relative to base-
line measurements (Fig 7E and G) although there was significant
variability in the magnitude of this effect between mice (Fig 7F and
H). This confirms that the peptide reduced the net synaptic activity
in the dorsal horn.
There was also a significant initial depression of the incoming
volley observed at 30 min after administration (Fig 7I–K). In half of
the mice, this was pronounced, as illustrated in Fig 7K. In the
remaining mice, a smaller depression was observed. To confirm that
this reduction was not due to damage to the dorsal roots or deterio-
ration in the health of the mouse in three of the mice, the peptide
was washed off the surface of the cord (Fig 7L). In all 3 mice,
consistent with the time course in von Frey experiments, the
incoming volley amplitude stabilized or started to return by 2 h,
demonstrating that the effect was related to the action of Tat-P4-
(C5)2, rather than a deterioration in the health of the animals of
damage to the roots.
Taken together, these data demonstrate that Tat-P4-(C5)2 in addi-
tion to the modulation of central sensitization may also exert its
action by suppression of excitability of the DRG axons at, or around,
the dorsal root entry zone, which are likely significantly more acces-
sible to the peptide than the secondary afferents in the spinal cord.
Discussion
In this study, we develop two cell-permeable, high-affinity inhibi-
tors, Tat-C5 and Tat-P4-(C5)2, of the PICK1 PDZ domain with the
purpose of disrupting the interaction of PICK1 with AMPARs and
thereby reverse central sensitization and its related maladaptive
plasticity believed to be associated with neuropathic pain. We
demonstrate that the five C-terminal residues of DAT (called C5) are
sufficient for maintaining affinity of the endogenous DAT ligand.
Conjugation of C5 to the HIV-derived Tat sequence (Tat-C5), which
rendered the peptide membrane permeably, serendipitously also
increased affinity more than 100-fold—an effect that was specific for
the PICK1 PDZ domain leading to increased selectivity. Our struc-
tural data suggest that this affinity gain results from interaction of
Tat with residues extending from the binding groove and all the
way to the opposite side of the PDZ domain.
In a parallel approach, we show that linking two C5 peptides
together with a PEG linker result in a 15-fold affinity gain, while
addition of the Tat sequence increased affinity further 50-fold
◀ Figure 7. Tat-P4-(C5)2 reduces functional CP-AMPAR expression and electrophysiological transmission in the spinal cord.A Representative images of kainate-induced cobalt uptake in spinal cord slices from p14 mouse pups treated with (i) saline, (ii) TNFa, and (iii) TNFa + Tat-P4-(C5)2.
Scale bar: 100 lm.
B Quantification of cobalt positive (black soma) cells. Each data point represents the average of 4-6 25-lm sections from a single 400 lm slice. Bars show means of 4–
6 slices, and error bars represent SEM (one-way ANOVA followed by Bonferroni’s multiple comparison test, *P < 0.05, **P < 0.01).
C In vivo electrophysiological recordings for the dorsal spinal cord before and after peptide administration following stimulation of the peripheral sural nerve at
intensities sufficient to activate C and Ad fibers. Illustration of the experimental setup indicates where measurements were made (image made using Biorender.com).
D Example of field potentials recorded in the same position before (black) and after (blue) peptide administration. The recording starts with a 1 mV calibration pulse
followed by a stimulus artifact (S), which is truncated for the figure and finally the field potential at a depth corresponding to lamina 1. Each trace is an average of at
least 10 successive trials.
E Bar chart showing the mean amplitude of the field potential at lateral positions in lamina 1 recorded before and approximately 30 min after peptide administration,
which was significantly reduced (Wilcoxon matched pairs, *P = 0.0313, W = 26, n = 7 mice, error bars: SEM).
F Line chart to show data from (E), as separate data points for individual mice expressed as a percentage relative to baseline measurements. From this, it can be seen
that the response was variable across mice with just over half showing a large reduction and the remaining mice only showing a relatively minor reduction (with no
reduction in one mouse). The von Frey thresholds for the individual mice before the experiment are shown next to each line.
G Bar chart showing the mean amplitude of the field potential at lateral positions in lamina 2 recorded before and 30 min after peptide administration, which was
significantly reduced (Wilcoxon matched pairs, *P = 0.0313, W = 26, n = 7 mice, error bars: SEM).
H Line chart to show data from (G), as separate data points for individual mice expressed as a percentage relative to baseline measurements. From this, it can be seen
there was reduction in all but 1 mouse, although the magnitude of the reduction was again variable across mice. The von Frey thresholds for the individual mice
before the experiment are shown next to each line.
I Example of cord dorsum potentials recorded following stimulation of the peripheral sural nerve. The initial 3 inflections represent the incoming volley of action
potentials along the afferent axons just before they enter the spinal cord. This was recorded before (black) and again 30 min post-peptide administration (blue). In
this particular example, an extreme drop in the amplitude of the incoming volley is observed post-administration.
J Bar chart showing that the mean amplitude of the incoming volley is reduced post-administration (Wilcoxon matched pairs, *P = 0.0156, W = 28, n = 7 mice, error
bar: SEM).
K Line chart to show data from (J), as separate data points for individual mice expressed as a percentage relative to baseline measurements. From this, it can be seen
that the response was variable across mice with half showing a large reduction and the remaining mice only a minor reduction.
L Amplitude of the incoming volley expressed as a percentage of the baseline recording prior to peptide administration. In these 3 mice, a reduction in the incoming
volley at 30 min post-administration is seen. After this recording, the remaining peptide was removed by washing the spinal cord and two further recordings made at
1 and 2 h. Here, it can be seen that the incoming volley does not deteriorate further but stabilizes or starts to return toward baseline levels confirming that the
initial reduction was not due to a deterioration in the health of the animal or damage to the roots.
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leading to more than 1,000-fold higher affinity for PICK1 than the
C5 peptide alone. Indeed, bivalency is well known to endow biologi-
cal molecules with high affinity/avidity and it is a well-known strat-
egy in receptor pharmacology (Portoghese, 2001; Krishnamurthy
et al, 2007) as well as in the case of the analogous bivalent inhibitor
of PSD-95 (Sainlos et al, 2011; Bach et al, 2012). However, whereas
these targets traditionally have been bivalent themselves, such as
the tandem PDZ domain of PSD-95 or strict PDZ dimers (Paduch
et al, 2007), we found that Tat-P4-(C5)2 works by bridging two PDZ
domains from individual PICK1 dimers to produce a novel tetra-
meric complex. Importantly, although analogous to our previously
published bivalent PSD-95 inhibitors, Tat-P4-(C5)2 does not bind
PSD95, suggesting that its function in pain does not relate to the
ability of PSD-95 to sustain hyperalgesia (D’Mello et al, 2011). Our
finding implies that bivalent inhibitors may hold an unforeseen
potential as high-affinity inhibitors—not only of tandem domains,
but also of PDZ domain proteins with propensity to oligomerize,
such as PDZ-GEF and LARG (Paduch et al, 2007).
Interestingly, the in vivo efficacy of Tat-P4-(C5)2 clearly exceeded
the one of Tat-C5, as well as the efficacy of two other PICK1 inhibi-
tors (myr-GluA2 and FSC231), with respect to relieving mechanical
allodynia in the SNI model of neuropathic pain. Tat-P4-(C5)2 was
likewise considerably better than Tat-C5 at; i) blocking the interac-
tion between PICK1 and GluA2 according to co-immunoprecipita-
tion analysis; ii) regulating GluA2 Ser880 phosphorylation, and iii)
reducing AMPAR surface levels. It is possible that this in part may
reflect better pharmacokinetic properties of Tat-P4-(C5)2 compared
to Tat-C5. That is, although distribution and membrane permeability
appeared to be better for Tat-C5 (Figs 4A and 5A), the in vivo stabil-
ity of Tat-P4-(C5)2 is likely better than that of Tat-C5 as suggested
by our plasma stability measurements (Fig EV1H). On the other
hand, the differences observed in the surface biotinylation assay
(Fig 6D), which was performed on spinal cord slices ex vivo, suggest
that also the pharmacodynamic properties of the two compounds
differ. This was specifically supported by the ability of Tat-P4-(C5)2,
but not Tat-C5, to affect GluA2 internalization in dissociated
hippocampal neurons.
From a mechanistic perspective, we propose that the differences
in efficacy between the two peptides relate to the increased ability
of Tat-P4-(C5)2 to dissociate a preformed cluster of PICK1 bound to
membrane-embedded ligands as observed on SCMSs. For multiva-
lent interactions, the macroscopic dissociation rate is composed
several individual microscopic dissociation rates. In the first dissoci-
ation step, the dissociation rate is balanced by an association rate
(rebinding) governed by the local concentration of the PDZ domain,
rather than global concentration of PICK1, which give rise to avidity
(Chi et al, 2010). Competitive inhibitors do not affect microscopic
association or dissociation constants and, thus, cannot increase
dissociation of monovalent interactions for which the macroscopic
dissociation rate equals the microscopic one. For bivalent interac-
tions, on the other hand, competitors may increase the macroscopic
dissociation rate, given that it can effectively compete with associa-
tion rate (rebinding) governed by the local concentration of the PDZ
domain in this case. Clearly, Tat-P4-(C5)2 does this much more effi-
ciently than both Tat-C5 (Figs 2E–G and EV2) despite only ~10-fold
difference in in-solution binding strength. We propose that PICK1
may assemble in a tetrameric configuration, similar to our SAXS
structure (Fig 3L), upon binding to membrane-embedded receptors.
In this scenario, peptide binding (monovalent as well as bivalent)
will interfere with PDZ interaction with ligand in the membrane.
We recently demonstrated, however, that PICK1 achieve most of the
avidity, not only from multiple PDZ interaction at the membrane the
avidity, but rather from interaction with the lipid membrane by the
amphipathic helix lining the BAR domain (Herlo et al, 2018;
Erlendsson et al, 2019) and likely also the CPC loop in the PDZ
domains (Shi et al, 2010) (Fig EV5, black dashed circles). Interest-
ingly, according to our SAXS structure (Fig 3L), binding of Tat-P4-
(C5)2 restricts orientation of the two PDZ domains, which may steri-
cally compromise these membrane-interacting motifs and thereby
also the rebinding events they govern (Fig EV5, bottom). Since Tat-
C5 will not restrict the PDZ orientation (Fig EV5, bottom), this could
explain why only Tat-P4-(C5)2 facilitate the macroscopic off-rate.
Our trafficking experiments performed in cultured hippocampal
neurons with Tat-P4-(C5)2 and shRNA suggest that PICK1 serves to
stabilize GluA2 on the surface by saving it from constitutive inter-
nalization. This is in concurrence with previous findings in the
PICK1 KO mice showing reduced extra-synaptic, surface GluA2
(Gardner et al, 2005); however, little work has been done on the
role of PICK1 in constitutive internalization of AMPARs. Several
studies, however, show that removal of or interference with PICK1
reduces activity-dependent internalization of GluA2 (Matsuda et al,
1999; Chung et al, 2000; Iwakura et al, 2001; Hanley et al, 2002;
Seidenman et al, 2003; Bell et al, 2009). Although this might seem
contradictory, we propose that the increased constitutive internal-
ization upon interference with PICK1 might, at least in some cases,
explain the reduced activity-dependent internalization, either due to
fewer mobile surface receptors for activity-dependent endocytosis to
act upon or because of normalization to different constitutive rates.
Note that our data would indicate a compromised PMA-dependent
internalization in the presence of Tat-P4-(C5)2 if normalized to the
respective constitutive internalization with and without peptide
(Fig 4H).
Interestingly, the surface biotinylation experiments suggest that
while Tat-P4-(C5)2 only modestly decreases surface GluA2 in the
spinal cord under basal conditions, it robustly reduces surface
GluA1 and GluA2 after induction of neuropathic pain. Moreover,
Tat-P4-(C5)2 reduced the TNF-induced increase in CP-AMPARs,
supporting that Tat-P4-(C5)2 is capable of potently modulating the
central sensitization often associated with neuropathic pain. Indeed,
in vivo electrophysiology confirmed reduced transmission in layer 1
and layer 2 after stimulation of peripheral afferents; however, the
measurements also revealed a robust decrease in the incoming
presynaptic fiber volley in agreement with previous detection of
PICK1 immunosignal in layers 1 and 2 of the spinal cord as well as
in DRGs (Wang et al, 2011). Whether this reflects a direct effect on
DRG excitability or indirect modulation by central neurons remains
to be determined but regards such mechanistic speculations this
finding is important when evaluating pharmacokinetic properties of
putative pharmaceutical with PICK1 as target in pain.
The selective engagement of PICK1 in AMPAR surface expres-
sion in the spinal cord after SNI-induced plasticity makes PICK1 a
very promising drug target. In analogy, PICK1 seems to serve a
specific role in potentiating AMPAR function during acquisition
and reacquisition of cocaine dependence (Bellone & Luscher, 2006;
Famous et al, 2008; Schmidt et al, 2013; Jensen, 2017), suggesting
that PICK1 is a promising target in addiction. Indeed, Tat-P4-(C5)2
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strongly reduces cocaine reinstatement in a self-administering
paradigm (Turner et al, 2020). Moreover, PICK1 has been evoked
as a putative target in ischemia (Dixon et al, 2009), Alzheimer’s
disease (Alfonso et al, 2014), and Parkinson’s disease (He et al,
2018).
In conclusion, we developed a high-affinity inhibitor toward the
PICK1 PDZ domain, Tat-P4-(C5)2. Tat-P4-(C5)2 obtains its high affin-
ity by cross-linking PDZ domains from individual PICK1 dimers and
demonstrates favorable pharmacodynamic properties to potently
alleviate neuropathic pain in both acute and chronic states, regard-
less of gender. We believe the peptide to be a promising lead
compound and, with the proper formulation to enable appropriate
administration, to be a strong candidate for extended pre-clinical
studies leading to future clinical trials for neuropathic pain following
peripheral nerve damage (Costigan et al, 2009).
Materials and Methods
Protein expression and purification
Escherichia coli cultures (BL21-DE3-pLysS) transformed with a
PICK1 encoding plasmid (pET41) were inoculated in 50 ml LB with
kanamycin overnight and transferred into 1 L LB medium with
kanamycin and grown at 37°C until OD600 = 0.6. Protein expres-
sion was induced with 1 mM IPTG and grown overnight at 20°C.
Bacteria were harvested and suspended in lysis buffer containing
50 mM Tris, 125 mM NaCl, 2 mM DTT (Sigma), 1% Triton X-100
(Sigma), 20 lg/ml DNase 1, and half a tablet of cOmplete protease
inhibitor cocktail (Roche) pr. 1 l culture at pH 7.4. Suspended pellet
was frozen at 80°C. The bacterial suspension was thawed and
cleared by centrifugation (F20 rotor, 36,000 × g for 30 min at 4°C).
The supernatant was collected and incubated with Glutathione-
Sepharose 4B beads (GE Healthcare) for 2 h at 4°C under gentle
rotation. The beads were pelleted at 3,500 × g for 5 min, and super-
natant was removed and beads were washed 2 times in a wash
buffer consisting of 50 mM Tris, 125 mM NaCl, 2 mM DTT, and
0.01% Triton X-100, pH 7.4. Washed beads were transferred to a
PD10 gravity column and were washed additionally three times.
Bead solution was incubated with thrombin overnight at 4°C under
gentle rotation. Cleaved PICK1 was eluted on ice, and absorption at
280 nm was measured on a NanoDrop 2000, and protein
concentration was calculated using Lambert–Beer’s law (A=ecl),
eA280PICK1 = 32,320 (cm*mol/L)
1. PDZ domains for selectivity test
were purified as described previously (Stiffler et al, 2007).
Peptide synthesis
Fluorescently labeled peptides were conjugated by either cysteine–
maleimide in the case of Oregon Green peptides or N-terminal Ahx link-
age in case of 5FAM labeling. All the FAM-conjugated and Oregon
Green-conjugated peptides were purchased, respectively, from TAG-
Copenhagen and Schafer-N. The peptide corresponding to the 5 most C-
terminal amino acids of the dopamine transporter C5, HWLKV, as well
as 5FAM-C5 5FAM-Ahx-HWLKV, Tat-C5 YGRKKRRQRRR-HWLKV,
5FAM-Tat-C5 5FAM-Ahx-YGRKKRRQRRR-HWLKV, and TMR-Tat-C5
TMR-Ahx-YGRKKRRQRRR-HWLKV, was purchased from TAG-Copen-
hagen.
Bivalent ligands PEG0-(HWLKV)2, PEG4-(HWLKV)2, PEG8-(HWLKV)2,
PEG12-(HWLKV)2, PEG28-(HWLKV)2, and 5FAM-P4-(C5)2 were synthe-
sized in-house by solid-phase peptide synthesis as described in Bach
et al (2009).
TMR-Tat-P4-(C5)2 (TMR-YGRKKRRQRRR-NPEG4-(HWLKV)2) and
Tat-P4-(C5)2 (YGRKKRRQRRR-NPEG4-(HWLKV)2) were synthesized
by Wuxi AppTec Co., Ltd. (China) accordingly. All peptides were
purified or delivered to > 95% purity verified by UPLC-MS.
Plasma stability
The peptides were dissolved to a final concentration of 50 lM in
human plasma (3H biomedical, Uppsala, Sweden) containing 2%
DMSO and incubated at 37°C. Aliquots (45 ll) were added directly
to 26 mg guanidine hydrochloride (GnHCl), vortexed, and incubated
for 2 min. 90 ll of 10% trichloroacetic acid (TCA) in acetone was
then added, and the suspension was incubated at 5°C for 24 h.
The suspension was centrifuged at 18,000 g for 5 min. The super-
natants were quantified by analytical C8 RP-HPLC and normalized
to the compound concentration at T = 0. Ligand recovery was
> 82%.
Fluorescence polarization
Fluorescence Polarization (FP) saturation binding was carried out
using an increasing amount of PICK1 incubated with a fixed concen-
tration of fluorescently labeled peptides as indicated. Competition FP
was done at a fixed concentration of PICK1 and indicated fluorescent
tracer, against an increasing concentration of unlabeled peptide. In
general, we sought to match tracer affinities to expected competitor
affinity for optimal assessment of actual binding strength (Huang,
2003). After mixing, the 96-well plate (a black half-area Corning
Black non-binding) was incubated for 20 min on ice, after which the
FP was measured directly on an Omega POLARstar plate reader using
excitation filter at 488 nm and long pass emission filter at 535 nm.
The data were plotted using GraphPad Prism 8.3 and fitted to either a
sigmoidal dose response for saturation experiments or One site
competition for competition experiments. Kis were automatically
calculated using the Cheng–Prusoff equation. All binding isotherms
were repeated at least twice with different purifications of PICK1 and
each time with 3 technical replicates. For selectivity screens, individ-
ual PDZ domains (42 domains + PICK1) with their respective fluo-
rescent ligand were spotted in 96-well plates. FP was measured in
parallel for plates incubated with buffer, 10 lM of C5 or Tat-C5.
Nuclear magnetic resonance
Isotopically labeled PICK1 PDZ-DAT C10 was expressed and purified
as described in Erlendsson et al (2014). The isolated unbound
PICK1 PDZ domain is not stable in solution; however, extending the
PDZ domain with a cleavable (PreScission C3 protease) linker
followed by the 10 C-terminal residues of DAT yields a highly stable
complex suitable for structural determination by NMR (Erlendsson
et al, 2014). Cleaving the linker in absence of Tat-C5 produces only
very minor structural perturbation. Chemical shift and/or intensity
changes observed when cleaving the linker in presence of a saturat-
ing concentration Tat-C5 can be directly related to the displacement
of C10 and subsequent binding of Tat-C5 peptide.
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NMR experiments were recorded on a Bruker Avance III HD
600 MHz spectrometer with a QCI quadrupole resonance cryoprobe.
All experiments were carried out at 25°C in 150 mM NaCl, 50 mM
Tris, pH 7.4, 10% D2O, 0.02% NaN3 (Sigma-Aldrich), and 0.25 mM
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) (Sigma-Aldrich).
We used a PICK1 PDZ-DAT C10 concentration of 200 lM. For the
competition binding experiments, we added Tat-C5 peptide to an
equimolar concentration of 200 lM. For the PreScission protease
(GE Healthcare)-induced competition binding experiments, we
subsequently added 10 U (10 U/ml). In both cases, we monitored
the change in amide chemical shifts by sequential acquisition of
1H-15N HSQC spectra recorded using 8 scans and 128 increments.
The backbone chemical shifts for the construct were obtained by
importing the peak list from the previous published NMR structure
of the PICK1-PDZ-DAT C10 (Erlendsson et al, 2014) construct
(BMRB entry: 18522, PDB ENTRY:2LUI). The imported peak list
was adapted manually in CCPN analysis 2.4.1. The peak list were
copied and adapted for each individual spectrum, and the chemical
shift perturbation was quantified as the Euclidian distance
(DdHN = √(0.5([dH
2+(a(dN
2)])) between the center position of the
original peak (before cleavage and addition of Tat-C5) and the posi-
tion of the resulting peak after addition of Tat-C5 or Tat-C5 and C3
protease, respectively. Where DdHN is the change in chemical shift
in ppm, dH is the change in position of the peak in the 1H dimen-
sion, dN is the change in position of the peak in the
15N dimension,
and a is a scaling factor between the two dimensions; in this case,
0.153 was used. The active peaks in the exchange between DATC10
and Tat-C5 were selected as being the residues with a chemical shift
perturbation greater than two times the standard deviation of the
mean chemical shift perturbation (2r = 0.077).
The HADDOCK (High Ambiguity Driven protein–protein Dock-
ing) (van Zundert et al, 2016) algorithm was used to dock Tat-C5
into the PDZ domain of PICK1. Only, the chemical shift perturbation
obtained was used as restraints in the docking. For the HADDOCK
modeling, the following residues were chosen as active: I33,G34,
I35, S36, I37, G40, C44, C46, L47, Y48, I49, Q51, G67, D68, E69,
K83, V86, K103, L104, and the algorithm was provided with a the
lowest energy structure of PICK1-PDZ-DAT C10 (PDB: 2LUI) where
the DATC10 was removed prior to docking (final residues: 23-107).
In Tat-C5 the residues, Y1, R3, R6, R7, Q8, H12, W13, L14, K15, and
V16 were chosen as active residues. A total of 1,000 structures were
initially docked, and the top 200 models were refined further using
simulated annealing followed by water refinement. The best cluster
of structures contained 42 structures, with a mean HADDOCK
score of 159.8  7.5 arbitrary units with an overall RMSD of
0.8  0.4 A˚.
HEK293-GT cultures and transfection
Human Embryo Kidney 293 GripTite cells (Thermo Fisher, catalog
number: A14150) (HEK293-GT) for SCMS were grown in 75-cm2
flasks until 70% confluent in Dulbecco’s modified Eagle’s medium
1965 with fetal calf serum and pen-strep antibiotics (DMEM
1965 + +). Cells were transfected with Tac-YFP-DAT C24 (pEYFP-C1
vector) (Erlendsson et al, 2019) using lipofectamine in opti-MEM
(Invitrogen) overnight. Cells were washed in PBS and detached
using 0.5% Trypsin with EDTA (Sigma-Aldrich). Cells were counted
in a Countess FL Automated Cell Counter (Thermo Fisher) using
Trypan blue (Sigma-Aldrich). Cells were seeded with a density of
200,000 cells pr. ml in a 6-well plate. Cells were then grown over-
night at 37°C in a humidified 10% CO2 atmosphere.
Supported cell membrane sheets
The SCMS was prepared as described in Erlendsson et al (2019). In
brief, round (Ø25 mm) coverslips (VWR 631-1346) were plasma
cleaned (Harrick plasma cleaner) and coated with 0.3 mM poly-L-
ornithine hydrobromide (Poly-ORN Sigma-Aldrich) for 30 min. Poly-
ORN was washed out with 2 ml MilliQ water. The 6-well plates
containing the cells expressing Tac-YFP-DAT C24 were washed twice
in MilliQ for a total of 1 min, to allow cells to swell. The swelled cells
were covered with a cover glass with the Poly-ORN-coated side
facing down. Dynamic pressure was manually applied to the cover
glass using the piston from a 12-ml plastic syringe for a total of
1 min. subsequent removal of the cover glass caused cell rapture
leaving SCMS on the surface of the cover glass. The cover glass was
covered in sheet buffer (10 mM HEPES, 120 mM KCl, 2 mM MgCl2,
0.1 mM CaCl2, and 30 mM glucose at pH 7.35) supplemented with
1 mg/ml BSA to block unbound Poly-ORN for 20 min on ice (in the
dark). Coverslips were washed 3 times with sheet buffer. Protein
solution (freshly prepared) was added and incubated according to
the experiment. In the experiments using a premixed PICK1:peptide
solution, 100 nM DY549-SNAP-PICK1 was incubated for at least
20 min with different concentrations of C5, Tat-C5, or Tat-P4-(C5)2
before addition to the cover glass. The protein:peptide solution incu-
bated with the SCMS-cover glass for 2 h in the dark on ice. In the
case of pre-binding of SCMS with PICK1, the SCMS was incubated
with 400 nM of DY549-SNAP-PICK1 for 1 h on ice in the dark.
Unbound protein was washed away with sheet buffer, and peptide
solutions were added and incubated for 2 h in the dark on ice. The
SCMS coverslips were then washed in sheet buffer and twice in PBS.
The SCMS was fixed for 40 min in 4% PFA, washed 3× in PBS, and
mounted onto objective glasses using Prolong Gold AntifadeTM
mounting medium (Life Science Technologies).
SAXS
Purified recombinant PICK1 (40 lM) was incubated with Tat-P4-
(C5)2 (20 lM). Precipitates were removed by centrifugation (5 min,
at 16,100 g at 4°C). Sample composition was verified by size-exclu-
sion chromatography (Superdex200, 10/300, 24 ml) to be homoge-
neous, and fractions were collected, pooled, and concentrated using
a 10 kDa cutoff spin filter (Millipore) to a final concentration of
2.45 mg/ml. The PICK1 samples was prepared by isolating the
dimer peak by collecting fractions from a HiLoad Superdex200 PG
16/600 (120 ml) and concentrating the dimer fractions to 3 mg/ml
using a 10 kDa cutoff spin filter. Concentration series was prepared
for both PICK1 and PICK1:Tat-P4-(C5)2, ranging from 0.5 mg/ml to
3 mg/ml and 0.5 mg/ml to 2.45 mg/ml, respectively. Samples were
transported in an ice bath to the Deutsche Electron Synchrotron
(DESY) facility, Hamburg, Germany. SAXS experiments
(Appendix Table S3) were conducted at the DESY, Hamburg,
Germany, using the P12 SAXS Beamline at the PetraIII storage ring
(Blanchet et al, 2015). Preliminary data reduction includes radial
averaging and conversion of the data into absolute scaled scattering
intensity, I(q), as a function of the scattering vector q, where
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q = (4p sinh)/k (where h is the half scattering angle) were done
using the standard procedures at the beamline (Blanchet et al,
2015). As part of the process, the individual buffer and sample
frames were looked through manually to check for radiation
damage. The frames where indications of radiation damage were
observed were removed, and the data averaging was done manually
for the remaining files. For PICK1:Tat-P4-(C5)2, data merging was
done by merging the low q-range data [0.01045–0.04036] A˚1 from
the 0.5 mg/ml sample together with the high q-range [0.03237–
0.2694] A˚1 data from the 2.45 mg/ml sample, with an overlap in
the [0.03237–0.04036] A˚1 q-range. The scattering data were
merged, and buffer subtracted curves analyzed by Guinier analysis
using the inbuilt analysis tools of the ATSAS program package
(Petoukhov et al, 2012). The p(r) functions were plotted using
http://bayesrelax.org/test/ with default settings. The shown data
were binned using WillItRebin with default settings for clarity.
Ensemble optimization method (EOM) (Bernado´ et al, 2007; Tria
et al, 2015) was used to fit the merged data using the all atom
relaxed MD model of the dimeric PICK1 BAR domain from Karlsen
et al (2015) together with the lowest energy structure of the PICK1
PDZ domain (PDB:2LUI) as fixed domains in the ensemble. The
unstructured C-terminal, N-terminal, and PDZ:BAR linker were
modeled using fully flexible dummy atoms and allowed for flexibil-
ity in the relative orientation of the domains. Tetrameric BAR
domain models were created using PyMOL by duplicating, translat-
ing, and rotating the dimeric BAR domain into suggested conforma-
tions of the PICK1 tetramer (Karlsen et al, 2015). EOM (Ranch)
(Bernado´ et al, 2007; Tria et al, 2015) was used to generate 10,000
models for each BAR domain configuration with 15 harmonics. The
models were fitted with either complete asymmetry or with 10%
symmetric structures (in this case the 10% symmetric structures).
EOM (Gajoe) (Bernado´ et al, 2007; Tria et al, 2015) was used to fit
the merged dataset to single pool (10,000 models) and multi-pool
ensembles. Gajoe was run using 1,000 generations in the genetic
algorithm with 100 ensembles, a non-fixed ensemble size, with a
maximum of 20 curves pr. ensemble and 100 repetitions. Fits were
evaluated on the basis of their v2 value and their Dmax and Rg
distributions.
Primary cultures of rat hippocampal neurons
Hippocampal neurons were prepared from prenatal E19 Wistar rat
pups (mixed gender). Brains were isolated from 6 to 8 rat embryos,
and brains were dissected in ice-cold dissection medium (HBSS
(Gibco) supplemented with 30 mM glucose (Sigma-Aldrich), 10 mM
HEPES (Gibco) pH 7.4, 1 mM sodium pyruvate (Gibco), 100 lg/ml
penicillin, 100 lg/ml streptomycin (Sigma-Aldrich)). The cerebel-
lum and meninges were removed, and hippocampi from both hemi-
spheres were dissected out. The hippocampi were treated with
papain (20 units/ml dissection medium, Worthington) for 20 min at
37°C, triturated (2 × 10 times) using differentially fire-polished
Pasteur pipettes, and filtered through a 70-lM cell strainer. Dissoci-
ated neurons were seeded at a density of 50,000–100,000 cells/
coverslip on poly-L-lysine (Sigma-Aldrich)-coated 25-mm glass
coverslips emerged in Neurobasal medium (Gibco 21103-049) (sup-
plemented with 2% (vol/vol) glutamax (Gibco 35050-038), 1% pen/
strep, 2% (vol/vol) B27 (Gibco 7504-044), and 4% FBS (Gibco
7504-044)). Cell cultures were grown in a 37 °C, 5% CO2, and 95%
humidified atmosphere. After 24 h, the growth medium was substi-
tuted with serum-free medium, and cells were grown for 21 days,
with addition of fresh growth medium every 3–4 days.
Transduction of hippocampal neurons
At 14 days in vitro (DIV), lentiviral constructs packed with
FUGWH1sh18eGFP (GFP-sh18) or FUGWH1sh18deleGFP (GFP)
were added to each well. FUGWH1sh18eGFP expresses a short hair-
pin (sh18) that targets endogenous PICK1 and a shRNA-resistant
eGFP-tagged PICK1, while the FUGWH1sh18deleGFP did not
contain sh18 (Holst et al, 2013; Jensen, 2017). Lentiviruses were
produced as described previously (Rasmussen et al, 2009).
Immunocytochemistry on hippocampal neurons
21 DIV hippocampal neurons were incubated with 5 lM TMR-Tat-
P4-(C5)2 or TMR-Tat-C5 or TMR-C5 for 1 h in conditioned media at
37°C, rinsed 3 times in PBS, and incubated with 5 lM of the
membrane dye DiO (Thermo Fisher) for 10 min at room tempera-
ture. After an additional 3 washes in PBS, the hippocampal neurons
were fixed in 4% PFA + 4% sucrose for 10 min at room tempera-
ture and subsequently washed three times in PBS and briefly in
MilliQ. The coverslips were mounted by using Prolong Gold Antifa-
deTM mounting medium (Life Science Technologies).
Permeability studies
20-22 DIV hippocampal neurons were incubated with 5 nM of TMR-
Tat-P4-(C5)2 for 1 h at 37°C, rinsed 3 times in PBS, and fixed in 4%
PFA + 4% sucrose for 20 min (10 min on ice and 10 min at room
temperature), rinsed again in PBS, permeabilized, and blocked in
0.05% Triton X-100 and 5% goat serum for 20 min at room temper-
ature, labeled with primary GFP antibody for 1 h at room tempera-
ture, and followed by staining with goat anti-rabbit Alexa-488. After
three final washes with PBS, the coverslips were mounted by using
Prolong Gold AntifadeTM mounting medium (Life Science Technolo-
gies). Quantification of the TMR-Tat-P4-(C5)2 peptide penetration
was carried out by ImageJ software. Images (16 bit) were masked
based on the 488-channel; the mask threshold was set at 1059 to
65535 and the background of the TMR-Tat-P4-(C5)2 at 726. The
TMR-Tat-P4-(C5)2 peptide mean intensity within the mask was
calculated for individual neurons, and each mean was divided by
the corresponding masked area.
Hippocampal neurons feeding assay
Live hippocampal neurons at 21 DIV were incubated with 20 lM
Tat-P4-(C5)2 or Tat-C5 or vehicle for 1 h before internalization in
conditioned medium with 2 lM TTX and 100 lg/ml leupeptin at
37°C. Surface AMPA receptors were labeled with the antibody anti-
GluA2 (10 lg/ml) for the last 15 min. After 2 washes in PBS,
neurons were treated with 1 lM PMA (Sigma-Aldrich) in condi-
tioned media (with or without Tat-P4-(C5)2, Tat-(C5)) for 10 min.
Neurons were fixed in 4% PFA + 4% sucrose for 5 min at room
temperature, blocked with 10% goat serum for 15 min, and stained
with anti-mouse Alexa-488 secondary antibody (5 lg/ml) in 3%
goat serum for 45 min. Following fixation for 15 min, cells were
permeabilized in 0.2% TX-100 for 5 min and stained with anti-
18 of 25 EMBO Molecular Medicine 12: e11248 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Nikolaj R Christensen et al
mouse Alexa-647 secondary antibody (1 lg/ml) in 3% goat serum
for 45 min. The slides were washed three times in PBS and once in
MilliQ and subsequently mounted to coverslips as described earlier.
After outlining individual neurons on the basis of surface signal
(488 nm), the mean intensity of the two channels was determined
and the signal ratio (647 nm (internalized)/488 nm (surface)) was
used as measure of internalization. A MatLab script was generated
to automatically calculate overall intensity ratio for each neuron.
Imaging
Imaging of SCMS, HEK293 cells, and hippocampal neurons was
done on a Zeiss LSM 510 confocal laser-scanning microscope,
equipped with an oil immersion objective, numerical aperture 1.4,
63× (Zeiss). For excitation of YFP, a 488 nm argon-krypton laser
was used, with detection using a 505–550 nm bandpass emission fil-
ter. Red dyes were excited using a 543 nm helium-neon laser, and
emission was detected using a 560–615 nm emission filter. Far red
fluorophores were excited using a 633 nm laser light from a helium-
neon (HeNe) laser source, and emitted fluorescent light was filtered
using a long pass filter.
Images were acquired at 1,024 × 1,024 pixels, 8-bit pr. pixel,
with 4-, 8-, or 16-line averaging scans. Images were treated using
ImageJ or Zen (Zeiss software).
Animals
SNI experiments were conducted on adult wild-type male mice (10–
15 weeks old at initiation of experiment) from Taconic Biosciences,
Denmark (C57BL/6JBomTac), unless otherwise stated. Mice were
left to habituate for at least 2 weeks before starting the experiment.
Mice were housed with littermates in a temperature-controlled
room maintained on a 12:12 light:dark cycle (tests performed during
light phase) and allowed access to standard rodent chow Altro-
min1342 (Brogaarden, Denmark) and water ad libitum.
All experiments were approved by the Animal Experiments
Inspectorate under the Danish Ministry of Food, Agriculture and
Fisheries, and all procedures adhered to the European guidelines for
the care and use of laboratory animals, EU directive 2010/63/EU.
All efforts were made to minimize stress or discomfort as well as
the number of animals used in each experiment.
Co-immunoprecipitation
Acute hippocampal slices and lysates preparation
Acute hippocampal brain slices were prepared from adult male
C57BL/6 mice (8–16 weeks old). The hippocampi were quickly
dissected and sliced (400-lm transverse sections) into ice-cold aCSF
buffer (124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.25 mM
NaH2PO4, 1 mM MgSO4, 2 mM CaCl2, and 10 mM D-glucose) and
placed in carboxygenated aCSF for 1 h for recovery. Slices were
then incubated with 20 lM Tat-P4-(C5)2 or Tat-C5 for 1 h followed
by 20 lM NMDA for 3 min for chemical LTD induction, in aCSF
buffer. Hippocampal slices were lysed in lysis buffer (50 mM Tris,
150 Mm NaCl, 0.1% SDS, 0.5% NaDeoxycholate, 1% Triton X-100,
5 mM NaF, and 1× Roche protease inhibitor cocktail at pH 7.4), and
protein was incubated overnight at 4°C with 5 lg of antibody (either
anti-PICK1 or anti-GluA2). Protein G agarose bead slurry was added
for 3 h, and the beads were then washed 3 times in lysis buffer.
Proteins were eluted in 2× Laemmli sample buffer at 100°C for
6 min before Western blotting.
Spinal cord lumbar tract total lysates preparation
Spinal cord lysates were prepared from 10-week-old C57BL/6 mice.
The animals were injected i.t. with 20 lM Tat-P4-(C5)2 or Tat-C5 and
sacrificed 1 h post-injection. The spinal cords were dissected in ice-cold
PBS1X by hydraulic extrusion according to the procedure described in
Richner et al (2017). The lumbar tracts of the spinal cords were quickly
harvested and lysed in lysis buffer. The same procedures described for
hippocampal slices were used to produce spinal cord lysates.
Transfected HEK293 cells total lysates preparation
The same procedures described for hippocampal slices were used to
produce HEK cell lysates.
Surface biotinylation
Spinal cords were extruded from 8- to 12-week-old naı¨ve and SNI
mice and lumbar tract was dissected as in Richner et al (2011), and
400-lM transverse slices were generated using a McIlwain tissue
chopper. Slices were then placed and separated in ice-cold aCSF
(124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.25 mM NaH2PO4,
1 mM MgSO4, 2 mM CaCl2, and 10 mM D-glucose) before recovery
in carboxygenated aCSF for 1 h. Slices were incubated for 1 h with
20 lM peptide inhibitor and subsequently incubated in 1 mg/ml
biotin (EZ-link sulfo-NHS-SS-Biotin: Thermo #21331) in ice-cold
carboxygenated aCSF for 45 min, washed 3 times in 10 mM glycine,
1 time in Tris-buffer saline (TBS) (20 mM Tris, 150 mM NaCl, pH
7.6), homogenized in lysis buffer (25 mM Tris, 150 mM NaCl, 1%
Triton X-100, 0.5% NaDeoxycholate, 0.1% SDS, 1 mM EDTA,
2 mM Naf, and 1 Roche protease inhibitor, pH 7.6) and centrifuged
at 20,000 g for 15 min. 500 lg of the supernatant was incubated
with Streptavidin dynabeads (Life Technologies: 65601) for 2 h.
Bead complexes were washed 3 times in lysis buffer and 1 time in
TBS. Proteins were eluted in 2× Laemmli sample buffer at 100°C for
8 min before Western blotting.
Spared nerve injury surgical procedure
Spared nerve injury (SNI) model was performed according to meth-
ods described in Richner et al (2011). Briefly, under isoflurane (2%)
anesthesia, the skin on the lateral surface of the left thigh was
incised and the biceps femoris muscle was divided lengthwise to
expose the three branches of the sciatic nerve. The common pero-
neal and tibial branches were tightly ligated and axotomized distally
to the ligation, while the sural branch was left intact. Animals were
monitored daily for signs of stress or discomfort but in all cases
recovered uneventfully.
Drug preparation and administration
For intrathecal (i.t.) drug administration, 7 ll was injected into
isoflurane anesthetized mice with a 10 ll Hamilton syringe (30 G) in
the intervertebral space between L4/L5 or L5/L6 at an angle of 30–
45° eliciting a Straub tail response as described previously (Hylden &
Wilcox, 1980). For intraperitoneal (i.p.) injections, 10 ll/g per
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mouse was administered with a 27 G needle. Drugs were diluted in
0.9% isotonic saline for both i.t. and i.p. injections.
Behavioral experiments
Von Frey testing of mechanical allodynia was performed as previ-
ously described (Richner et al, 2011). In short, mice were placed in
red plastic cylinders on a wire mesh (15-min habituation prior to
testing). von Frey filaments (0.02–1.4 g) were applied in ascending
order to the lateral part of the hind paws. Each von Frey filament
was applied five times and a positive response in at least three out
of five stimuli determined the threshold level. A positive response
was defined as sudden paw withdrawal, flinching, and/or paw lick-
ing induced by the filament. Testing was performed blinded toward
the nature of injected substance and by the same female researcher
to avoid person-to-person variation and gender bias.
The paw withdrawal threshold (PWT) was estimated by using
the following formula:
PWT ¼ Number of response failures
Total number of trials
 ððfilament Aþ 1grÞ
 ðfilament AgrÞÞ þ filament Agr
Fluorescence peptide administration
10-week-old SNI male mice were injected with 20 lM Tat-P4-(C5)2
i.t. and transcardially perfused with cold 0.1 M phosphate buffer
(PBS) at time 0, 30, 60, and 120 min post-injection. Naı¨ve animals
were subjected to the same procedure after i.t. injection of 20 lM
Tat-P4-(C5)2 or Tat-C5 and perfused 60 min post-injection. All spinal
cords were isolated by hydraulic extrusion and post-fixed in PFA
4% for 8 h. Spinal cords were subsequently cryoprotected in 30%
sucrose, embedded in Tissue-Tek OCT, and sliced at 20 lm thick-
ness by Cryostat Leica CM3050 S.
Immunohistochemistry
Mounted slides were dried at room temperature, rinsed in PBS1X
twice for 5 min each, and incubated in blocking buffer containing
5% goat serum, 1% BSA, 0.3% Triton X-100 in 1× PBS, for 90 min
at room temperature. The slices were incubated in blocking buffer
with primary antibody overnight at 4°C. On the second day, sections
were rinsed 3 times in washing buffer (0.25% BSA, 0.1% Triton X-
100 in PBS) 10 min each. Secondary antibodies Alexa-488 or Alexa-
647 were diluted in washing buffer and the slides incubated 45 min
at room temperature. After one wash in washing buffer and addi-
tional washing steps in 1× PBS, sections were air-dried and mounted
with DAPI Fluoromount-G (Southern Biotech) mounting media.
Regarding the tissue distribution of Tat-P4-(C5)2 or Tat-C5, the
slides were washed 5 min in PBS, air-dried, and mounted with DAPI
Fluoromount-G mounting media.
Epifluorescence microscopy
Epifluorescence microscopy was performed using a Zeiss axios-
can.Z1, with a plan-apochromat 10×/0.45 objective (Carl Zeiss).
LED light sources were used as follows, DAPI (353-nm excitation,
50-ms exposure, 460/70-nm bandpass filter), Alexa-488 (493-nm
excitation, 50-ms exposure, 525/50-nm bandpass filter), TMR-568
(577-nm excitation, 100- to 300-ms exposure, 600/70-nm bandpass
filter), and Alexa-647 (653-nm excitation, 200-ms exposure, 690/50-
nm bandpass filter). All channels were imaged covering a total of
around 6 lm of the 20-lm-thick spinal cord slices.
Kainate-induced cobalt uptake
Postnatal day 14 (P14), C57BL/6 mouse pups of both genders were
decapitated and their spinal cord was dissected out in ice-cold
oxygenated stabilization buffer (139 mM sucrose, 32.5 mM NaCl,
2.5 mM KCl, 10 mM MgSO4, 12 mM D-glucose, 24 mM NaHCO3,
1 mM NaH2PO4, 0.5 mM CaCl2). The lumbar part was embedded
with cyanoacrylate in a 5% agar block, and 400-lm slices were cut
on a vibrating microtome (Thermo Scientific Microm HM 650 V).
The slices were divided into three groups and left to recover in
oxygenated stabilization buffer at RT for minimum 60 min. Tissue
from each animal was subjected to all three experimental groups.
Slices were pre-incubated with 20 lM Tat-P4-(C5)2 (as indicated) in
oxygenated stabilization buffer for the last 30 min of incubation in
stabilization buffer. Slices were then transferred to oxygenated
uptake buffer (139 mM sucrose, 57.5 mM NaCl, 5 mM KCl, 2 mM
MgCl2, 1 mM CaCl2, 10 mM HEPES, 12 mM D-glucose) followed by
addition of 20 lM Tat-P4-(C5)2 and 20 nM TNFa (as indicated) for
10 min. Co2+ and kainate were added to a final concentration of
2 mM Co2+ and 200 lM kainate for 20 min to all three experimen-
tal groups. Cobalt loading was terminated by 2 × 5 min wash in
uptake buffer containing 3.5 mM EDTA followed by treatment with
0.12% (NH4)2S for 6 min to precipitate intracellular Co
2+. Slices
were rinsed in PBS and fixed in 4% PFA for 3 h at 4°C followed by
cryoprotection in 30% sucrose o/n at 4°C. Slices were rinsed in
PBS, embedded in OCT, and cut to 25-lm slices on cryostat.
Sections were processed to enhance the CoS reaction by silver inten-
sification as described in Engelman et al (1999). Due to non-specific
Co2+ labeling in the outer parts of the 400-lm slices, these were
excluded for analysis. Average cell count of 2–4 of the 25-lm slices
from each 400-lm slice was used for quantification. Images were
acquired using a Zeiss Widefield microscope using a 20× objective.
For quantification, pictures were captured using identical exposure
settings. Pictures were imported into ImageJ (version 2.0.0-rc-41/
1.50b), and cells with black soma were counted manually. Analysis
and counting were performed blinded by investigators.
In vivo electrophysiology
Electrophysiological recordings were performed in vivo in adult
decerebrate mice. The preparation has been previously described
extensively (Meehan et al, 2012, 2017). Briefly, the initial surgery
was performed under isoflurane anesthesia (1.5–2%), including the
insertion of tracheal cannula for subsequent artificial ventilation,
the dissection of the sural nerve (on the injured side), and a dorsal
hemi-laminectomy between vertebrae levels T12-L1 (exposing
spinal levels L3-L4). Mice were then placed in a modified Narishige
frame and attached to a ventilator (CWE, 72 breaths/min). Cran-
iotomy was performed, superficial blood vessels cauterized, and the
entire brain rostral to the superior colliculus removed. The void was
packed with surgical to prevent bleeding. After approximately
20 of 25 EMBO Molecular Medicine 12: e11248 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Nikolaj R Christensen et al
10 min, this was removed to confirm complete decerebration before
being replaced followed by removal of isoflurane from the ventila-
tion flow. Throughout the experiment, the temperature of the
animals was kept stable at approximately 37°C using a heat lamp
and heat blanket thermostatically controlled by a rectal thermome-
ter. Expired pCO2 was also stable throughout the experiments.
The dissected peripheral nerve was hooked on a custom-made
bipolar stimulating electrode, and the spinal cord mechanically stabi-
lized using vertebral clamps above and below the segments of inter-
est. A silver ball electrode was placed on the lateral edge of the
laminectomy, and a reference electrode placed down the side of the
ribcage on the ipsilateral side. This recorded the cord dorsum potential
that shows the incoming volley of sensory input in the dorsal roots.
The peripheral nerve was stimulated at thresholds to ensure
maximal stimulation of the high-threshold Ad and C fibers (Steffens
et al, 2012). This electrode was manually moved rostral and caudal
to determine the site with the maximal incoming volley. The dura
was then removed from the dorsal surface at this region, and this
site was used for recordings. A glass microelectrode filled with
potassium acetate was inserted in the spinal cord using a motorized
micro-drive, and field potentials were recorded at depths corre-
sponding to laminae 1 and 2 using an Axoclamp 2b amplifier (Axon
Instruments). These measurements were made at locations in the
lateral gray matter indicated in Fig 7C as these regions have been
shown to show maximal field potentials (Schouenborg, 1984).
Both the incoming volley and field potentials were further ampli-
fied and filtered using Digitimer (UK) amplifiers, digitized using a
Power 1401 digital to analogue converter (CED, UK), recorded, and
analyzed using Spike 2 software (CED, UK). All measurements were
made from averages of at least 10 successive stimulations (per-
formed in Spike 2). The incoming volley was measured as the peak-
to-peak amplitude from the first 3 inflections of the cord dorsum
potential as illustrated on Fig 7C and D. Baseline recordings were
initially performed, followed by application of the peptide to the
surface of the spinal cord, and the recordings performed again 20-
30 min later in the same location. In 3 mice, the spinal cord was
washed immediately after the second measurements were made and
recording of the incoming volley repeated after 1 h and 2 h.
Antibodies
Western blots, fixed primary hippocampal neurons, HEK 93 cells,
and tissue sections were analyzed with primary antibodies
directed against the following: GFAP (rabbit polyclonal, Dako Cat.
No. Z0334; dilution 1:1,000 for immunohistochemistry), NeuN
(mouse monoclonal, Millipore Cat. No. MAB377; dilution 1:100
for immunohistochemistry), PICK1 (rabbit polyclonal JH2906
kindly provided from Richard Huganir’s laboratory, 5 lg for
immunoprecipitation) and PICK1 (mouse monoclonal clone 2G10
custom generated; dilution 1:500 for Western blot), GFP (rabbit
polyclonal, Abcam Cat. No. Ab290; dilution 1:500 for immunocy-
tochemistry and Western blot), GluA2 (mouse monoclonal, Milli-
pore Cat. No. MAB397; dilution 1:100 for immunohistochemistry
and 1:1,000 for Western blot), pS880 GluA2 (mouse monoclonal,
Millipore Cat. No. MABN103; dilution 1: 500 for Western blot),
GluA1 (rabbit monoclonal, Millipore Cat. No. 04-855; dilution
1:500 for Western blot), Pan-Cadherin (rabbit polyclonal, Cell
Signaling Cat. No. #4068; dilution 1:500 for Western blot), b-actin
HRP-conjugated (mouse monoclonal, Sigma Cat. No A3854.; dilu-
tion 1:10,000 for Western blot), and IgG-negative controls (normal
mouse, Santa Cruz Cat. No. SC-2025, 5 lg; rabbit polyclonal, Cell
Signaling 27295, 5 lg for Western blot).
As secondary antibodies, we used Alexa Fluor 488-conjugated
goat anti-rabbit IgG (Thermo Fisher scientific, Cat. No. A-11034;
dilution 1:500 for immunohistochemistry and immunocytochem-
istry), Alexa Fluor 647-conjugated goat anti-mouse IgG (Thermo
Fisher scientific, Cat. No. A-21236; dilution 1:500 for immunohisto-
chemistry and immunocytochemistry), Alexa Fluor 488-conjugated
goat anti-mouse IgG (Thermo Fisher scientific, Cat. No. A-11029;
dilution 1:500 for immunocytochemistry), and (HRP)-conjugated
secondary antibodies for Western blotting (anti-mouse/anti-rabbit,
Abcam Cat. No. ab99632/ab99697; dilution 1:10,000).
Statistical analysis
Statistical analyses were performed as indicated specifically for indi-
vidual experiments. Significance level was set to P < 0.05. GraphPad
The paper explained
Problem
Neuropathic pain affects 7–10% of the world population with higher
prevalence in women and elderly. Current medication, including anti-
epileptics, antidepressants, and opioids, provides only partial pain
relief and comes with considerable side effects. Consequently, there is
an urgent need for better treatment. The causes for development of
neuropathic pain include diabetes mellitus, treatment with
chemotherapeutics, and herpes zoster, which all cause damage to the
peripheral nervous system leading to increased central pain percep-
tion. This central sensitization involves insertion of excess glutamate
receptors in the dorsal horn synapse, and direct modulation of the
glutamatergic transmission by glutamate receptor antagonist to
obtain better efficacy has been pursued, but clinical development has
been discontinued due to adverse side effects.
Results
This paper demonstrates a refinement of this approach by targeting
the insertion of excess glutamate receptors in the hyper-sensitized
condition rather than blocking the receptors themselves. This was
achieved by development of a peptide that can inhibit the scaffold
protein PICK1, which has previously been evoked as a molecular
target in pain treatment because it sustains insertion of a subtype of
glutamate receptors. Injection of the peptide in the spinal cord effec-
tively relief pain in an animal model of neuropathy, whereas injection
in the paw of the injured hind limb was ineffective, suggesting a
central mechanism of action. This was supported by electrophysiologi-
cal in vivo measurement in injured animals, which confirmed that the
peptide reduced spinal cord transmission.
Impact
The approach presented here evokes a novel mechanism of action for
pain relief and potentially provides a potent tool for interfering with
excessive glutamate receptor transmission in pain. Importantly, since
the peptide only affect disease-related receptor insertion, we do not
anticipate major impact on basal neurotransmission. Consequently,
with the proper formulation to enable appropriate administration, the
peptide is a strong candidate for extended pre-clinical studies leading
to future clinical trials for neuropathic pain following peripheral nerve
damage.
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Prism was used for data analyses. For pharmacological, imaging,
and biochemical experiments, sample size was chosen according to
common practice with at least 3 independent determinations. More
replicates were added in several of the biochemical experiments
upon reviewer request. For SNI experiments, mice were randomly
assigned to individual experimental groups and von Frey testing
was performed blinded toward the nature of injected substance and
by the same female researcher to avoid person-to-person variation
and gender bias. A pre-specified group size of 8 animals was chosen
based on previous experience with pharmacology in the SNI model.
In 6B and H, animals were taken down prior to experiment reducing
the measured n, but in both cases significance was not compro-
mised. Exception is Fig EV4D, where only 4 animals were used for
the positive control gabapentin because of its well-known effect
size.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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